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Herein, two translational issues related to the development of cell therapy 
discoveries into therapeutic products, are addressed. Firstly, analysis of whether 
the manipulations required to transfer cells from cell culture conditions to a target 
tissue affect cellular characteristics was performed. It was shown that processing 
primary murine mesenchymal stem cells (MSCs) into a concentrated cell 
suspension, drawing them up into a syringe and immediately ejecting them, caused 
a significant viability decrease. Leaving the cells within the syringe chamber at 
room temperature for prolonged time periods caused to a further decrease in 
viability. However, cells that were viable post-ejection were found to be functional 
with regard to their ability to attach and proliferate. Reducing the ejection rate or 
using the antioxidant 
-acetyl cysteine did not significantly improve viability, 
although using a wider bore 22g needle did improve viability.  
 
Secondly, the feasibility of a cell transportation device that could store viable cells 
under room conditions was assessed. The development of such a transportation 
device would remove the need to cyropreserve cells during transit, which has 
many flaws. Human MSCs were found to enter a reversible proliferative arrest 
phase whilst under room conditions, allowing them to be stored for up to 11 days, 
before rapidly decreasing in viability. The accumulation of ammonia was 
identified within the cultures, and the introduction of a zeolite material was found 
to partially remove this ammonia and improve viability over 7 days. A means of 
developing a concentrated cell culture media, using a freeze-drying technique, was 
found not to comprise cell viability, whilst allowing the nutrient volume to be 
reduced, thus potentially making the transportation device more compact. 
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However, the introduction of a modified release nutrient gel, consisting of 
alginate, did not provide any significant effect on viability.  
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Here, the potential of regenerative medicine, and, more specifically cell therapy, as 
therapeutic applications, will be reviewed. Mesenchymal stem cells (MSCs) will 
be discussed as a cell source, as well as the clinical areas where MSC cell therapy 
techniques may be beneficial. The translational obstacles related to moving cell 
therapy from the laboratory to the bedside will be summarised, finishing with the 
aims of this thesis. 
 
1.1 – The development of regenerative medicine 
Regenerative medicine is an overarching term referring to the development of 
technologies that can restore the function of diseased or aged organs. The research 
strategies working towards this regenerative aim include tissue engineering  
(TR), cell therapy, organ and tissue transplantation, as well as therapies that induce 
endogenous regeneration. Currently, regenerative medicine is a research topic of 
great importance, mainly because of the potential that this form of therapy could 
provide in the clinic and because of the significant drawbacks of current tissue-
restoration techniques. 
 
There is no question that organ or tissue loss has a massive impact on healthcare, 
both on a global and an individual level; by 2010, the worldwide market for 
regenerative medicine has been estimated to be as high as $ 500 billion1. 
 
1.2 – Cell therapy 
Cell therapy can be considered as the delivery of an active cell suspension without 
an extracellular matrix (ECM) component. Cell therapy is a technique applied to 
disease states where the cells require little structural or biochemical support, and 
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has the obvious advantage in that the systems tend to be less complicated than 
scaffold-based TE systems.  
 
The earliest successful example of cell therapy was the blood transfusion, which is 
still used in modern medicine to replenish lost blood from trauma or surgery, or to 
treat severe anaemia and thrombocytopenia. Developments within this field aided 
our understanding of compatibility and sterility2, which are useful in the 
development of current allogeneic cell therapy developments. Cell therapy 
methods are also applied in the form of allogeneic haemopoetic stem cell 
transplantation, performed to replenish the number functioning lymphocytes in 
patients with severe multiple myeloma or leukemia. If the patient’s immune 
system can tolerate the transplant, this form of therapy can be effective. 
 
 Another disease state that has been shown to have benefited from cell therapy 
developments is insulin-dependent diabetes mellitus (IDDM). In IDDM, a specific 
discrete pancreatic β cell population is rejected by the immune system, which not 
only releases insulin, but, more importantly, constantly monitors blood glucose 
levels and releases the correct amount of insulin accordingly, providing a level of 
glucose control that no current technology can. The fact that the disease is solely 
caused by the lack of a certain cell type makes it ideal for cell therapy3. The 
transplantation of these cells using a well-established Edmonton Protocol can 
provide insulin independence in IDDM patient for up to two years4. Unfortunately, 
akin to kidney transplantation, there are a severe lack of donors, and this is made 
worse by the loss of functional cells during the operation, thus the operation 
requiring up to 3 donors per recipient. However strategies are being developed to 
provide a limitless supply of insulin releasing cells3,5.   
 
There are two main forms of cell therapy, depending on whether the cells are 
sourced from the patient intended to be treated (autologous) or elsewhere 
(allogeneic). 
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1.2.1 – Autologous cell therapy 
Patients of all ages carry adult stem cells that are able to, to a certain extent, 
replicate and replace cells that become damaged or age (although the number of 
stem cells does decrease as a human ages)6. The aim of autologous cell therapy is 
to utilise these adult stem cells by extracting them from the body with minimal 
inconvenience to the patient, expanding them 
 	 if necessary, and then 
delivering them to the area of required regeneration, where the cells hopefully 
engraft, differentiate into functional tissue, and ultimately treat the disease. 
 
The main advantage of autologous cell therapy is that, because the cells delivered 
are the patient’s own, there is no risk of immune rejection. However, autologous 
cell therapy would be complicated to perform in a hospital setting, as essentially 
two operations would be required (one to remove the stem cells, and one to deliver 
the cells), with a time period of up to a month between operations to allow the 
cells to replicate to an adequate population for delivery. 
 
Another issue with autologous therapy is the high potential variability in 
effectiveness and adverse effects this treatment may have. No one procedure used 
to obtain stem cells from a patient could yield a pure stem cell population, but 
instead a mix of numerous cell types, so, even after isolating and expanding, it is 
unlikely that the delivered suspension will not have a variable number of other 
cells. And, even if the delivered cell suspension could be processed to be pure and 
of the same cell number for every patient, the level of bioactive molecules that the 
cells would release would be highly variable and ultimately affect how effective 
the treatment is from patient to patient7. 
 
Finally, in order for this form of therapy to be available in the future, cell culture 
facilities would be required either in or near to the clinic where the procedure 
would take place. Because cell therapy products cannot be sterilised after 
processing, like some medical devices, every facility would require stringent good 
manufacturing practice (GMP) guidelines7,8 to ensure sterility is maintained 
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throughout the processing. This would ultimately be very costly to operate. This 
would mean that, if these therapies were found to be effective in the future, only 
the wealthy countries would have access to them. 
 
Research has been carried out to assess whether autologous cell therapy is still 
effective if the cell population is not expanded, but delivered in the same operation 
as when they are removed. If this were possible, this would lead to a reduction in 
hospital time per patient and remove the need for any cell culture facilities. One 
report suggests that expanding human bone marrow stromal cells reduces their 
differentiation potential, and that using a non-expanded cell population is more 
effective in diseases involving osteogenic, chondrogenic or adipogenic 
differentiation9. Early cell therapy trials, focusing on improving cardiac tissue post 
myocardial infarction, delivered unselected bone marrow aspirate to the heart but 
showed little benefit, supposedly because bone aspirate has a very low percentage 
of functional progenitor cells ( < 0.1 %)10. Hernigou and co-workers showed that 
concentrating the bone marrow aspirate by centrifugation led to an improvement in 
bone engraftment when using the marrow to treat tibial nonunion11.  
 
An exciting avenue of cell therapy may develop from recent insights into induced 
pluripotency. In 2006, it was shown that terminally differentiated fibroblasts could 
be reprogrammed into a stem cell-like state by introducing four transcription 
factors. These cells had many of attributes of ESCs; they were able to proliferate, 
were able to differentiate into all 3 germ layers and were able to form teratomas in 
immunodeficient mice12. The multiple viral vectors could, however, potentially 
cause genetic alterations and therefore could not be delivered to a patient. 
However, Kaji   recently showed that it is possible to induce stemness in 
human skin cells using a transgene that could be removed once reprogramming 
had occurred13. This technology could potentially simplify how cells are harvested 
from the patient, but the limitations with directing specific cell differentiation 
could lead to the development of teratomas in patients treated with induced 
pluripotent stem cells; studies have suggested that the tumorigenic potential of 
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these cells is at least equal to hESCs, if not or more14. Moreover, the issues in 
terms of cell expansion facilities and patient-to-patient variability mentioned 
previously would still be present. 
 
1.2.2 – Allogeneic cell therapy 
All the flaws of autologous cell therapy previously mentioned could be at least 
partially rectified by using cells from allogeneic sources; because the cells would 
not need to be the patient’s own, the cells could be processed at a specialised 
facility, and shipped to the clinic. Processing techniques could be optimized to 
ensure that batch-to-batch variability is kept to a minimum, and essentially only 
one procedure would be required in order to provide the treatment, thus reducing 
hospital costs and inconvenience to the patient. 
 
Allogeneic cell therapy also provides the option of using embryonic stem cells 
(ESCs) to treat disease; these are, in theory, a more effective cell source than adult 
stem cells because their pluripotency allow them to potentially develop into all 
three germ layers, providing any cell required, provided that the correct biological 
cues are used. However, the ethical considerations involved with sourcing ESCs 
means that their availability is scarce, and this in turn encourages the research in 
induced pluripotency mentioned previously13.  
 
*#+#+#*$(
	,

The main problem of allogeneic cell therapy is immune rejection; if the cells are 
not the patient’s own, there is always a chance that the patient’s immune system 
will recognize it as non-self and clear them. How significant this problem is has 
been under much debate; some studies have shown little or no immune response 
when allogeneic cells have been delivered 
, whilst some have shown a clear 
activation. 
 
ESCs are thought to be “immune privileged”, mainly because, during healthy 
pregnancy, the maternal immune system is not seen to reject the embryonic tissue 
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containing nonmaternal antigens inherited paternally15. However, even in their 
undifferentiated state, ESCs express low levels of major histocompatibility 
complex (MHC) class I molecules, and, as these cells differentiate, these levels are 
seen to increase, accelerating the immune response16. 
 
Allogeneic studies using mesenchymal stem cells (MSCs) have been shown to 
produce little immune response; Arinzeh  showed that allogeneic MSCs were 
able to aid the repair of a critical size bone defect with no adverse immune 
response17. This is thought to be due to MSCs lacking MHC class II molecules on 
their surface18, providing immunoprotection that CD28-mediated co-stimulation 
nor -interferon pretreatment could activate19.  
 
However, in separate reports, MSCs have been less successful; De Bari and co-
workers found that MSCs used for osteogenic engraftment were only effective in 
immunodeficient or immunosuppressed mice20, and similar findings have been 
reported when MSCs were used for myogenic regeneration21. This contrast in 
results may be due to level of miss-match between donor and recipient7, or may be 
due to an increased immune response as the MSCs differentiate, as with ESCs16.  
 
Methods are currently being developed to prevent the immune rejection of stem 
cells. One such method involves microencapsulating the stem cells in order to hide 
their immunogenic surface proteins. This method was seen to be effective in 
preventing rejection during xenograft murine ilset transplantation, though when 
scaled up to dog, primate or human models, no protection was seen22. 
 
1.3 – Mesenchymal stem cells 
Mesenchymal stem cells (MSCs) have become a popular cell source for cell 
therapy research because they are easily expandable 
 	, and may have the 
ability to differentiate into useful cell lineages 
, such as bone, cartilage, fat, 
cardiac muscle and potentially neurons. They are also straightforward to isolate 
from patients through bone marrow aspiration or adipose tissue biopsy6, though 
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the former can be a painful procedure for the patient. Because of their popularity 
within cell therapy research, all studies detailed in this thesis were carried out 
using primary MSCs. 
 
Mesenchymal stem cells are broadly classed as the non-haemapoetic stem cells 
present the bone marrow, and are called mesenchymal because they can 
differentiate into multiple mesodermal cell lineages. MSCs represent a very small 
fraction of the bone marrow, but can proliferate to a graftable number within a 
month 
	. 
 
One key issue with MSCs is their broad characterization. The surface markers 
used by different groups to extract MSCs from bone marrow include CD13, CD29, 
CD31, CD44, CD54, CD63, CD73, CD105, CD106, CD140b, CD166 and Strol, 
among others6, but no robust marker definition has been deduced for MSCs. What 
makes this definition more complicated is that culture expanded MSCs may lose 
some markers, but still remain active as a stem cell23. Until a definition of an MSC 
is determined, MSC-based therapeutics are likely to be highly variable from batch 
to batch. 
 
The differentiating potential of MSCs into certain cell types has been heavily 
scrutinised. It is established that MSCs have the ability to form osteocytes, 
chondrocytes, adipocytes and myocytes. However reports on the neural and 
hepatic differentiation are mixed, as reports stating these forms of differentiation 
have been questioned on the grounds of the possibility of cell fusion6,24.  
 
It has become clear that the ability of an MSC to differentiate into a certain cell 
type 
	 does not necessarily correlate with its ability to form that cell type 

. For example, the reports showing myogenic differentiation 
  may 
actually be  
 myogenesis or cell fusion with resident myoblasts, as 
described by Gonçlaves and co-workers25. 
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Another issue regarding the use of MSCs for cell therapy relates to studies that 
show that they enter senescence and lose their stemness soon after isolation and 

	 culture26. In the majority of cases, even when tissues usually abundant in 
patients, such as adipose tissue, are used to source MSCs, expansion is required 
before delivery in order to yield an adequate cell number (especially concerning 
allogeneic therapy), but this expansion may reduce the quality of the cells. Studies 
have shown that, even under ideal culture conditions, passaging human 
mesenchymal stem cells (hMSCs) over 25 times can lead to a significant increase 
in cell doubling time and a decrease in differentiation potential27. However, recent 
research has shown that the stemness of the cells 
	 can be improved using 
methods such as lentiviral gene transfer28. 
 
The application of MSC-based cell therapy to treat specific disease states will now 
be discussed. Table 1 summarises the main clinical areas where MSC-based cell 
therapy has been attempted 
. 
 
1.3.1 – Cardiac regeneration 
The vast majority of cardiac tissue is composed of terminally differentiated 
myocytes that are unable to replicate nor repair damaged areas after a myocardial 
infarction (MI). This means that, even if a patient survives after an MI, the heart is 
weakened and the patient is then more prone to congestive heart failure (CHF). 
Cell therapy may be able to encourage the regeneration of damaged myocardium 
and reduce the risk of the patient suffering from CHF. 
 
To date, numerous clinical trials have been completed where bone marrow stem 
cells have been delivered to the myocardium to promote healing, involving over a 
thousand patients29,30,31,32,33. Many of these studies show a significant increase in 
left ventricular ejection fraction (LVEF) after the intervention, but this increase 
tends to be small; in the REPAIR-AMI trial only a modest increase of 2.5 %
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34 C
hapter 1                                                                                                            G
eneral Introduction 
Condition Human? Results Comment 
Cardiac Regeneration33 Yes Small improvement in LVEF, though not long-
term 
Tested on over 1000 patients 
GVHD43 Yes Significant improvements in the majority of 
patients 
Phase II trial 
Bone Regeneration11 Yes Improvements in non-union fractures Supportive scaffold required 
 
Cartilage 
Regeneration48 
 
Yes 
 
ACI effective in regrowing articular and patellar 
cartilage 
 
Chondrocytes much more effective 
than MSCs 
Diabetes Mellitus52 Yes Differentiated insulin-producing MSCs decreased 
insulin requirements by up to 50 % 
Difficulty in producing cells that 
monitor blood glucose, like β cells 
Skin Graft53 No MSCs were able to prolong skin graft survival MSCs possibly prevent immune 
rejection 
Lung Inflammation60 No MSCs reduce bleomycin-induced inflammation in 
mice 
 
Crohns Disease54 Yes Adipose-derived MSCs healed 75 % of treated 
fistulas  
Phase I trial 
Corneal Burns57 No MSCs prevented unfavourable corneal 
remodelling post-trauma in rats 
 
Multiple Scherosis55 No MSCs effective in preventing demyelination in an 
autoimmune encephalomyelitis model 
A more accurate model may be 
required 
Cerebrovasular 
Accident34 
No IV administration of MSCs reduced infarct 
volume, though no evidence that they migrated to 
brain 
 
 
Table 1.1. Overview of the mesenchymal stem cell-based cell therapy studies that have been carried out, both on human and 
animal subjects. LVEF: left ventricular ejection fraction; GVHD: graft versus host disease; MSC: mesenchymal stem cell; ACI: 
autologous chondrocyte implantation; IV: Intravenous 9
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compared to control was seen35. When considering that a patient surviving after 
their MI may still experience a decrease in LVEF by as much as 20 %, this 
increase is small indeed (though cell therapy has been seen to have a greater effect 
when the MI has caused a greater level of damage to the heart than average)36. 
Furthermore, Martin-Rendon and co-workers suggest that patient-centered 
outcomes should be measured as well as clinical outcomes, such as exercise 
capacity and quality of life33. This suggestion is supported by Chang  , who 
found that maximal exercise capacity did not correlate accurately with LVEF six 
months after treatment29, though this may be due to a discrepancy in the level of 
exercise the patients did and the level of exercise they reported after the procedure. 
 
A somewhat irrational design approach has been used in choosing the correct cell 
type to provide maximum benefit to the patient; few studies exist comparing the 
regenerative capacity of different cell types, so the method of delivering an 
autologous unfractionated bone marrow cell suspension has become popular36. 
However, this approach is pragmatic in that, by not selecting a specific cell subset, 
more cells are can be harvested from a relatively lower volume of bone marrow 
aspirate (as the cells are not expanded 
 	 to make the operation quicker), 
reducing the possible discomfort caused to the patient. 
 
Little is known as to how the cells provide any benefit 
 . Cell-tracking 
studies show that less than 5 % of the cells remain within the myocardium after 3 
months37, suggesting that the beneficial effects seen from the therapy are provided 
through a mechanism other than cell engraftment, forming functional tissue. It has 
been predicted that the cells may release cytokines that stimulate favourable 
outcomes, such as angiogenesis, the prevention of cardiomyocyte apoptosis and 
increased tissue perfusion38. This paracrine hypothesis is supported by the fact that 
this form of therapy did not show any benefit one year after treatment in the 
BOOST trial39, suggesting that, after a year, the paracrine benefits on angiogenesis 
and perfusion had dwindled, and the level of surviving engrafted cells had 
decreased to a level that no longer provided significant benefit. 
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Assuming that this paracrine effect does occur, when the cells are delivered may 
relate to further benefit to the patient; it is known that levels of the cytokine 
vascular endothelial growth factor (VEGF) increase acutely (24-48 hours after 
infarction) and sub-acutely (7days after)33. The REPAIR-AMI trial showed that 
significant additional benefit was seen when the stem cells were delivered more 
than 6 days after reperfusion35, suggesting that the cells may amplify the release of 
VEGF, providing additional benefit. Martin-Rendon   suggested that, due to 
the acute increase in VEGF post-MI, cell therapy may be even more effective if 
delivered within 24 hours of the MI33, although logistically this would be difficult 
to perform. 
 
Recently, Korf-Klingebiel   assessed whether bone marrow cells provide a 
paracrine effect by analysing the benefit provided by bone marrow supernatant. 
Here they showed the supernatant was able to protect rat cardiomyocytes from cell 
death induced by simulated ischaemia 
	40. (
 assessment is required, but 
this study suggests that the beneficial effects of the bone marrow cells could be 
mimicked by a cytokine delivery system, which would remove all the 
complications regarding cell therapy.  
 
The cells are delivered to the myocardium either transvascularly (via a blood 
vessel) or via a direct injection. Transvascular strategies are suited for a recently 
reperfused heart, as that is when chemoattractants and cell adhesions molecules are 
more prevalent. The most effective delivery method in terms of delivering a high 
concentration of cells homogeneously is by intracoronary artery infusion using an 
over-the-wire balloon catheter. This catheter inflates to maximise the contact time 
between the cells and the intracoronary wall. For the experienced physician, this 
process is straightforward and can be completed within an hour36. 
 
Direct injections into the ventricular wall are the preferred route for patients with 
chronic myocardial ischaemia and when scar tissue has formed. However, this 
method creates islands of cells with limited blood supply that are prone to hypoxia. 
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Injecting into the border zone of the infarct can also be technically complicated, 
and it is unclear how well the perforation caused by the needle recovers36. 
 
1.3.2 – Graft-versus-host disease (GVHD) 
One step further from the reports stating that allogeneic MSCs have little or no 
effect on the host’s immune response are the reports that suggest MSCs have an 
immunomodulatory role41. Little is known about how MSCs modulate the immune 
response, but it has been hypothesized that MSCs may:- 
- engage cell-to-cell contact with T cells (which is required before T-cell 
suppression takes place42), 
-  suppress effector T cells through the release of various growth factors, such as 
transforming growth factor β, hepatocyte growth factor, indoleamine 2,3-
dioxygenase, prostaglandin E2 and nitric oxide
43, 
- down-regulate immunoglobulin production43 and/or 
- up-regulate MHC class II markers, reducing the natural killer cell 
cytotoxicity43. 
Studies also showed that MSCs, once delivered, were able to accumulate in either 
sites of organ damage, inflammation, or cancer42,43, which means that MSCs may 
not have to be delivered to the specific required site of action to provide benefit. 
 
In order to explore the immunomodulatory of MSCs, researchers have clinically 
assessed the effectiveness of MSC cell therapy for treating graft-versus-host 
disease (GVHD). GVHD is a common complication of allogeneic haematopoietic 
stem cell transplantation, where the host rejects the transplant. In a case report, 
transplanted allogeneic MSCs, delivered intravenously, were found to treat a 
patient with severe GVHD44. This led to a clinical trial, where 60 million MSCs 
were delivered, and this showed an impressive response rate of 70 %45. In a phase 
II study containing 55 patients with steroid resistant GVHD, no patients had any 
side effects from the therapy, 30 patients had a complete response and a further 9 
showed improvement46. However, it was suggested by Miura and co-workers that 
this therapy may make the patients more prone to infections, due to its 
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immunosuppressive action. This may have led to 3 deaths in the study (2 from 
bacterial septicaemia, 1 from adenovirus infection)47, though GVHD in itself does 
weaken the immune system also. 
 
1.3.3 – Bone regeneration 
During certain types of fracture, the MSCs within the skeletal tissue contribute 
towards remodeling the bone so that it is able to bear weight again, providing a 
pool of osteoblasts necessary for the formation of mineralized matrix. However, in 
certain situations, such as non-union fracture, or in certain diseases such as 
osteoporosis, arthritis and cancer, normal remodeling processes are impaired. 
MSCs have been shown to be an effective cell source to aid the repair in non-
union fractures11,23, but only with a scaffold present that can provide a three-
dimensional environment for the MSCs to proliferate in, and provide some 
element of weight-bearing capacity at the injury site before the cells have had time 
to mineralize48. For these reasons, many developments in bone regeneration have 
been TE-based, rather than cell therapy-based.  
 
1.3.4 – Cartilage regeneration 
Autologous chondrocyte implantation (ACI) (or autologous chondrocyte 
transplantation) is mainly used to replace articular or patella cartilage (within the 
knee joint). Until recently, the most effective method of treating articular cartilage 
damage was to replace the joint with an artificial construct. However, because 
these artificial joints are stiffer than the surrounding bone, damage to the healthy 
bone often occurs49. 
 
ACI is a treatment aimed at patients suffering from grade III or grade IV 
cartilaginous lesions, which can form as a result of local trauma or a disease such 
as osteoarthritis. Within these lesions, the hyaline cartilage is avascular, aneural 
and, especially with age, with limited reparative capacity. Also, due to the limited 
migratory ability of chondrocytes, healthy cartilage surrounding a defect is often 
unable to fill the defect49. 
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ACI is a very effective treatment for repairing injured cartilaginous areas, but only 
when performed with chondrocytes isolated from the joint (which may include 
MSCs also), rather than MSCs alone. MSCs are found to produce fibrocartilage 
that lack the mechanical properties required to support the underlying bone, 
especially for high-demand patients50. Also, isolating and expanding the 
chondrocytes is no more complicated a procedure than the equivalent MSC 
isolation. 
 
Autologous chondrocyte implantation has also been assessed for regenerating the 
intervertebral disc to help alleviate lower back pain51, and a recent EuroDISC 
clinical trial did suggest effectiveness52, but only with chondrocytes isolated from 
the vertebrae.  
 
1.3.5 – Diabetes mellitus 
Trivedi and co-workers presented work where they were able to differentiate 
adipose-derived MSCs into insulin-secreting cells. These cells, when delivered to 
diabetic patients, were found to decrease insulin requirements by up to 50 %, with 
a mean follow-up of 2.9 months53. The authors carried out the study using 
allogeneic cells (obtained from family donors), but there appears to be no reason 
why the cells could not be extracted from the autologous source to reduce the level 
of immune rejection. Optimisation of the delivery process and the number of cells 
delivered may make this a curable treatment, though there was no evidence to 
show that these transformed cells, like β cells, are able to release insulin in 
response to increasing blood glucose levels. 
 
1.3.6 – Other diseases 
The breadth of clinical manifestations where the use of MSC therapy has been 
investigated is staggering. Due to the immunomodulatory effects of MSCs, they 
have been shown to prolong skin graft survival 
54, and may be beneficial in 
treating Crohns disease42,43,55 (an autoimmune disease affecting the gastrointestinal 
tract) and multiple sclerosis56 (an autoimmune disease affecting the central 
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nervous system). Also, due to the cell’s ability to accumulate in cancerous tissue, 
the cells may be used as a delivery device, enabling the targeting of therapeutics 
directly to the cancer57. The beneficial paracrine effects that MSCs provide in 
cardiac tissue have also been reported intraocularly, and show promise in treating 
corneal burns58. The cell’s ability to target inflamed areas, with excessive ECM 
deposition, may make MSCs effective as a vector used to help treat diseases of the 
lung59,60, and studies have shown that MSCs have the ability to reduce bleomycin-
induced inflammation and fibrosis within the lungs of mice61. Finally, recent work 
suggesting that MSCs could differentiate into hepatocyte-like cells 
  could 
lead to the development of MSC-based hepatic-cell therapy, though only if it can 
be proved that cell differentiation is not actually cell fusion62. 
 
1.4 - Understanding the cell’s tolerance to cell therapy-based manipulations 
With regard to many of the animal and clinical studies described above, 
methodological parameters, such as how many cells to deliver, which cells to 
deliver, how many doses would be required etc., were based on little if any 
	 
evidence. Furthermore, assessment of the effectiveness of a cell therapy trial was 
often clinically performed63, with little regard of how and why a specific cell 
therapy was effective. 
 
When considering the survival of the cells during the cell therapy process, the 
procedure can be split into two; (i) the effects of the processing of cells from either 
a tissue-culture flask, or, if not expanded, from the tissue biopsy, to the target 
organ/tissue via a delivery device, such as syringe or catheter, and (ii) the effects 
on the cells 
 once delivered (Figure 1.1).  
 
1.4.1 – Tracking cell migration and activity once within the target organ 
It is very difficult to track the migration of cells once administered, and the task 
becomes more complicated when requiring information regarding cell activity.  
The following imaging methods have been used in order to follow the progress of 
the cell:- 
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Figure 1.1 Simple schematic to show the areas of uncertainty during the cell 
therapy process. The first area of uncertainty assesses how cells are affected by 
the delivery process. The second area of interest questions how cells produce the 
required improved clinical outcome, and how the cells engraft 
  
 
Cells expanded 

	 
Cells within the 
target organ 
? 
 
? 
Improved 
Clinical 
Outcome 
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Optical imaging. Bioluminescence imaging is a highly sensitive method, and 
has been used to assess the distribution of MSCs within an organ over time. 
Fluorescence reporter probes are used less often due to low signal-to-
background ratios57. There is no radiation with this method, but this method is 
not, so far, clinically applicable37. 
- Two-photon microscopy, where a signal is produced when 2 photons of a low 
energy excite a fluorophore in a quantum event, have the advantage over optical 
imaging techniques in that the level of light scattering (which causes image 
blurriness) is much reduced. This means that imaging can be performed at 
much greater depths, from 100 µm with optical imaging, to upto 1 mm. This 
allows more opportunities for imaging to be performed without any damage to 
the tissue64. 
- Magnetic Resonance Imaging. Cells are directly labeled with magnetic 
resonance contrast agents, providing good resolution. Issues do also arise with 
regard to the sensitivity of detection, and whether the label affects the activity 
of the cells37,57,65. 
- Radionucleotide Imaging. These methods can have a good penetration depth, 
and provide quantifiable data, such as cell number 
 57,66. However, the 
radiation may have an effect on the therapeutic cells. 
- Reporter Gene Imaging. Cells are transfected with a viral reporter gene. 
Transfected cells can then be detected following the intravenous administration 
of a radio-labeled or optical reporter probe which binds to the specific 
translated protein. This is the most effective method of tracking active cells, as 
the expression of the protein requires the cell to be viable57. This method can 
also be used to track differentiation. However, the signal produced is weak, and 
there is a risk of genetic modification within the host37. 
- Quantum dot imaging. When delivered to murine ESCs, quantum dots were 
found to cause no significant effects on viability, proliferation or 
differentiation. These dots were found to be easily imaging fluorescently, even 
within deeper tissues, where MRI may not effective67. However, this technique 
still provides little information with regards to cell viability or function, and 
- 
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there is the possibility of the quantum dots separating from the delivered cells 

. 
None of these imaging methods are ideal for tracking the delivered cells, 
especially if the safety of the host is of concern, as is the case with clinical trials. 
 
1.4.2 – Analysing the effect that the cell delivery process has on cell fate 
Few studies have analysed the effect of processing the cells for cell therapy 
applications on cell viability and activity. The factors during this procedure that 
could have an effect on viability include:- 
- the stresses experienced during the recovery of cells from culture i.e. 
trypsinisation from tissue culture plastic, centrifugation of cells, removal of 
cells from a tissue-culture incubator, resulting in an increase in pH and a 
decrease in atmospheric temperature, 
- cell stresses resulting from a localised high cell concentration within the 
delivery system (produced when there are restrictions in the volume of solvent 
that the cells can be suspended in), such as alterations in pH, aeration levels, 
nutrient availability, toxic metabolite accumulation, and cell-cell signaling, 
- physical cell insult due to the passage through the delivery system (such as the 
shear stresses induced by drawing up or expelling the suspension from a 
syringe needle/catheter, bubble entrainment/bursting by inversion of delivery 
device) leading to necrosis or induction of apoptosis,  
- storage conditions, sterility and preparation of delivery device (e.g. “shelf 
life” of system, temperature, lag time before delivery). 
 
Veraitch  assessed the impact that manual handling had on ESC viability and 
directed differentiation capacity, promoting the need for automated cultivation 
systems. Exposing the ESCs to prolonged periods (up to 3 hours) under ambient 
temperatures saw a decrease in proliferation, as did the passage of the cells 45 
times through a 500 µm diameter capillary (to simulate the pipetting of cells68). 
One could speculate from these results that, a prolonged period at room 
temperature for a cell therapy suspension would have a more drastic effect on the 
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cells (as the cells would be at a higher concentration). Similarly, the passage of 
mammalian cells through a narrow bore would have a more pronounced effect as 
the bore would be narrower than 500 µm. Moreover, in order to have the cells 
within the delivery device, in theory, all of the manipulations described in the 
paper would need to be carried out, adding a negative predisposition to the cells 
before they endure the passage through the delivery device. However, the extent at 
which these negative effects would occur is greatly unclear. 
 
One of the only published studies assessing the viability of the cells post-ejection 
from a delivery device is described in Kondziolka  . The paper assessed the 
viability of neuronal cells within a concentrated (3.3 × 107 cells/ml) suspension, 
using a trypan blue exclusion method, after being drawn up through a 25 gauge 
bore (260 µm internal diameter) and expelled through a catheter of similar 
diameter. Surprisingly, they found a decrease in viability by almost half after this 
manipulation as acceptable for their studies69. 
 
One could argue that, provided that the majority of cells survive the delivery 
process, information regarding the fate of the cells post-administration makes little 
difference to the number of cells delivered, as little is known with regard to the 
number of cells required to provide a clinical benefit. Furthermore, in some 
studies, a large variance in the number of cell delivered is seen as the researchers 
aim to deliver as many cells as possible in each individual case (Le Blanc  is 
an example of this)46. However, a small level of cell death within a concentrated 
cell population could have a significant effect on the cellular characteristics of the 
remaining viable portion and the host environment through the release of cytotoxic 
agents such as tumour necrosis factor α70. Moreover, studies analysing the effect 
of the cell delivery process could also explore alterations to the process that may 
optimize cell viability, such as refrigerating samples, increasing the needle bore 
diameter, reducing the ejection rate, among others.   
 
Chapter 1  General Introduction 
   
  20 
1.5 - The complications surrounding the provision of allogeneic cell therapy 
products 
1.5.1 – Regulatory complications 
With so little known with regard to the mechanisms involved in a cell’s 
effectiveness to treat a clinical state, regulatory bodies, such as the Food and Drug 
Administration (FDA), want to make sure that these therapies are consistent, safe, 
pure and efficacious71. The FDA separates cell products into those that require 
“minimal manipulation”, such as traditional blood products, which must be 
processed following Good Tissue Practice (GTP), and those that require more than 
minimal manipulations. The latter must be processed under Good Manufacturing 
Practice (GMP) as well as GTP, and are considered as investigational new drugs 
(INDs) with regards to the pre-market clinical trials required8. GMP, and to a 
lesser extent GTP, present the need for costly GMP facilities that ensure sterility 
within the cell therapy product. 
 
Regulatory bodies also require cells that are free from cell debris and pyrogens, 
potent and of a specified cell number at the point of delivery8. A cell viability of 
80 % or more is also expected, as well as a method of displaying repeatable 
potency72. 
 
1.5.2 – The storage and transportation of cell therapy products 
Researchers accept that, for cell therapy to be clinically available in the future, 
research is required in effective storage and transportation methods for the final 
product73. The logistical limitations of transporting autologous cell therapy 
products was a significant issue that the company CellTran® faced with their 
product MySkin®. MySkin® is a product based on autologous keratinocytes 
delivered on transfer disc, developed to treat a range of dermatological conditions, 
such as burns and diabetic ulcers. They found that regular repeated applications of 
this product initiated wound healing in 18 out of 21 patients with diabetic ulcers in 
a randomized controlled trial74, but found that the application of the products was 
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complicated by the logistical challenges associated with sampling, processing, 
storing and delivering the autologous cells. 
 
One method that may provide a storage solution, and improve the ease of 
transportation, is cryopreservation. Bone marrow cryopreservation for the use in 
treating GVHD has been found in most reports to be at least as effective in treating 
the disease as freshly isolated bone marrow, although the number of patients 
treated in the studies was low. One report showed an improvement in treatment 
when using the frozen cells compared to fresh cells (though the improvement may 
have been due to adjuvant medicines administered, which were not kept constant 
throughout the studies). However, a significantly greater number of cryopreserved 
transfusions were found to be contaminated with bacteria, compared to fresh 
transfusions, and this is thought to be caused by the greater level of manipulation 
required for the preserved cells75. 
 
Another issue with cryopreservation is the use of cryopreservant. One 
cryopreservant used often is dimethyl sulphoxide (DMSO), which, at a 10 % (v/v) 
concentration (optimal for cryopreservation), was found to be toxic to the patient, 
causing a significant increase in nausea, vomiting and fever75. However, research 
in increasing the rate of freezing may reduce the concentration of cryoprotectant to 
non-toxic levels76. Strategies are also being developed in using alternative non-
toxic cyropreservants, utilising the mechanisms used by freeze-hardy plants; by 
encouraging the accumulation of disaccharides, such as sucrose and trehalose, into 
the cells, the sugars can act as a cryoprotectant77. Olarewaju   applied the 
disaccharide trehalose, together with propylene glycol, to embryonic stem cells 
and showed efficient viability retention following rapid freezing and thawing78. 
 
Flasza and co-workers describe storing and transporting human dermal fibroblasts 
(HDFs) under refrigerated (2-8 °C) conditions during the phase I trials of the 
Intercytex® product, ICX-SKN. The HDFs were stored on fibrin constructs in 
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sterile pouches containing CO2-independent transport medium. This method was 
able to keep the HDFs alive and proliferative for up to 5 days79. 
 
Flasza   state that the ability to transport cells without cryopreservation 
removes the need for specialised storage or complicated recovery methods79. For 
these reasons, companies, such as Genzyme® are developing cell-specific 
refrigeration technologies to possibly meet the demand of cell products in the 
future that would require distribution80. 
 
A study by Lane  showed that the viability of human bone marrow stromal 
cells completely diminished when stored at room temperature at the concentration 
of 2 × 106 cells/ml81. This study suggests the need for complex systems in order to 
prolong cell viability under room conditions (or, arguably, that is it not possible to 
retain cell viability under room conditions). One group have developed a method 
of preserving limbal epithelial cells at room temperature for 7 days in organ 
culture medium, allowing them to be transported with ease. Limbal epithelial cells 
are used to treat patients with a ocular limbal stem cell deficiency and the 
preservation of these cells are important because human donors are in demand, and 
the cells can take several weeks to culture into an epithelial sheet, making the 
scheduling of the operation complicated. Utheim , found that, by culturing the 
cells onto an amniotic membrane, suturing the membrane onto a polyester 
membrane, and transferring this to a bath of organ culture media, 84 % of viable 
cells could be retained after a week82. Although an impressive finding, this study 
was carried out in media containing xenogeneic material, which may cause prion-
based complications when delivered to the host. Moreover, the cells were kept at 
temperatures (23 °C) higher than the temperatures the cells may be exposed to if 
transported outside of a cell culture facility or clinic.  
Chapter 1  General Introduction 
   
  23 
1.6 – Aims 
There are two distinct aims of the research presented here. The first aim is to 
assess the effect that parenteral delivery has on the MSC’s ability to thrive. Section 
1.3 clearly describes the potential of MSCs to treat numerous diseases, but little is 
known as to whether cells are affected by the delivery process, and this may have 
fundamental implications for the development of future cell therapy products. 
 
The objectives in order to achieve this aim are to:- 
- assess how the time left within the syringe chamber at room temperature affects 
mMSC viability, apoptotic activation, morphology and proliferative ability 
(Chapter 3), 
- assess whether seeding the cells onto microparticles before being left within the 
syringe chamber improves mMSC viability (by allowing the anchorage-
dependent cells a surface to adhere to) (Chapter 3), 
- assess how parameters such as ejection rate, needle gauge, anti-oxidant 
concentration, affect the viability of the mMSCs using flow cytometry as an 
analytical method (Chapter 4), 
- compare the viability of mMSCs left within the syringe chamber against those 
left within an eppendorf (Chapter 3 and 4). 
 
The second aim is to develop a means of transporting cell therapy products, 
keeping cells viable at room temperature and under atmospheric conditions for up 
to 7 days. The ability to keep cells alive under these conditions removes the need 
for special delivery, and keeping the cell alive over such a time period means that 
international distribution may be feasible. It is hypothesized that, if the required 
nutrients are delivered to the cells at a controlled rate, and the metabolites which 
are toxic are removed from the system, and gaseous exchange can occur through a 
permeable membrane, primary human MSCs should survive under these 
conditions. 
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The objectives in order to achieve this aim are to:- 
- develop a proof-of-concept, where the effectiveness of a toxin adsorbent 
(Chapter 5) and a nutrient supply (Chapter 6) within a simple well-plate 
configureation is shown,  
- assess which key metabolites need to be adsorbed (Chapter 5), and which key 
factors are needed to be delivered via the delivery system (Chapter 6), 
- develop an adsorbent that is able to adsorb the key toxins (Chapter 5), 
- develop a delivery system that can provide the required nutrients at a steady 
rate (Chapter 6). 
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2.1 - Materials 
2.1.1 – Cell cultures 
Adult CD1 mice used to obtain the mMSCs were sourced from the Biomedical 
Science Unit, University of Nottingham, UK. Both the Biomedical Science Unit 
and the personnel have up-to-date Home Office licenses, allowing them to 
sacrifice the mice prior to isolation using asphyxiation. 
 
Primary hMSCs were obtained from TCS CellWorks, Buckingham, UK. On 
receipt the cells were at passage 1. 
 
2.1.2 – General chemicals 
Sterile preparation of stock solutions and chemicals were performed either by 
filtration through a 0.22 µm Whatman sterile filter and/or autoclaving at 121 °C at 
1 bar for 1 hour. Most general chemicals were purchased from Sigma-Aldrich 
(Poole, UK) unless otherwise as stated as below: 
 
Alamar blue was bought from Invitrogen®, Paisley, UK. CellTiter AQ One 
Solution Cell Proliferation® assay kit was bought from Promega, Southampton, 
UK. High molecular weight 85:15 PLGA was purchased from Lakeshore 
Biomaterials, Birmingham, AL, USA. The zeolite used in this research was a kind 
gift from Bear River Zeolite, Preston, Idaho, USA. Other reagents can be found in 
the appendix. 
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2.1.3 – Apparatus and consumables 
Primaria 6-well culture dishes and hypodermic needles were bought from Falcon, 
Becton and Dickinson Ltd., Oxford, UK. Tissue culture flasks (75 cm2, 175 cm2 
and triple 175 cm2) were bought from Nunclon, Denmark. Costar 96-well flat-
bottom, non-treated, polystyrene assay plates and Transwell® polyester membrane 
inserts, 24 mm diameter, were purchased from Corning, NY, USA. Ten µl glass 
syringes with a luer lock tip (model 1701LT) were purchased from Hamilton®, 
Bonaduz, Switzerland. The Havard® syringe pump (model PHD 2000) was bought 
from Havard Apparatus®, Holliston, Massachusetts, USA.  Magna nylon 0.45µm 
membrane filters, 500 µl eppendorfs, Sterilin® petri dishes, 15 and 50 ml sterile 
centrifuge tubes, 10 ml sterile pipettes, automatic pipette fillers, 1 ml 200 µl and 3 
µl pipette tips, 0.22 µm filters were bought from Fisher Scientific, Loughborough, 
UK. Whatmann® filter paper was purchased from Sigma-Aldrich, Poole, UK. 
Scintillation vials were supplied by Canberra-Packard, Pangborne, UK. The 
Mettler-Toledo SevenEasy® pH meter, the improved Neubauer haemocytometer 
and parafilm were purchased from Scientific Laboratory supplies, Nottingham, 
UK. The Bio-Tek KC4 microplate reader was purchased from Fisher Scientific, 
Loughborough, UK. The MFX plate reader was bought from Dynex, Chantilly, 
VA, USA. The class II double HEPA-filtered flow safety cabinets were purchased 
from Walker®, Derbyshire, UK. The tissue culture Incusafe® incubators were 
bought from Sanyo, Loughborough, UK. The Leica DM-IRB/E inverted 
microscope was purchased from Leica Microsystems /., Milton Keynes, UK, 
and the Volocity® image software was bought from Improvision, Coventry, UK. 
 
2.2 - Methods 
2.2.1 - Murine mesenchymal stem cell isolation 
Primary murine mesenchymal stem cells (mMSCs) were isolated in-house 
following the standard protocol as previously described by Da Silva Meirelles and 
Nardi, which has recently been updated83,84. Unbroken bone was isolated from the 
hind legs of CD1 mice and the bone marrow was exposed using a simple end 
fracture. Bone marrow/cell homogenate was flushed out with complete mMSC 
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media using a hypodermic needle. Erythrocytes were removed with the use of 1 ml 
of red blood cell lysis buffer, incubating at 37 °C for 1 minute, centrifuging (250 
g, 4 minutes), and removing the supernatant fraction. The resultant cell mass was 
transferred to a 25 cm2 T-flask containing complete mMSC medium, and 
incubated for 72 hours before the non-adherent cells were removed.  
 
2.2.2 – Culture conditions 
Cells were cultured and maintained, 
	, as monolayers in tissue culture flasks 
using either complete mMSC or hMSC medium (appendix 1.1 and 1.2 
respectively). Cells were routinely cultured in a humidified-atmosphere tissue-
culture incubator at 37 ˚C and with 5 % CO2 and never allowed to reach greater 
than 80 % confluency at any one time. For routine detachment and passaging, a 
standard trypsinisation protocol was performed. The cell monolayer was rinsed 
once with phosphate-buffered saline (PBS) prior treatment with trypsin/EDTA 
solution (appendix 1.7), at 37 ˚C for approximately 5 minutes (based on visual 
detachment). Inactivation of the trypsin was achieved by the addition of an equal 
volume of complete medium. This suspension was then transferred to a centrifuge 
tube before being spun down at 250 g for 4 minutes. The cell pellet was then re-
suspended in the appropriate volume of fresh complete medium or re-seeded at the 
desired cell density in the corresponding culture vessel. This was then returned to a 
tissue culture incubator or used for experimentation. Back-up cultures were 
maintained using a separate and independent supply of medium and solutions. 
 
Both mMSCs and hMSCs were passaged up to 25 times (as suggested in Pal , 
2008), or when noticeable differences in morphology or in cell doubling times 
were observed, before being used within the studies27.  
 
All aseptic techniques used were performed in accordance with the ATCC 
guidelines. All manipulative tasks were confined to class II safety cabinets under 
ACGM Containment level 2 regulations. The disposal of cells and other biological 
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wastes were either autoclaved and/or disinfected in accordance with ACGM 
regulations. 

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A standard method was used to transfer cells to the well or transwell of a 6 well 
plate. After detachment using trypsin (2.2.2), cell counts and viability 
determination, to create the correct viable cell concentration, were performed 
using the trypan blue exclusion technique (appendix 4.3).  Cells were then spun 
down at 1200 rpm for 4 minutes, the supernatant was removed, and cells re-
suspended in a volume of media to provide a final cell concentration of 105 
cells/ml. This final concentration (1 ml) was plated onto either the well of a tissue-
culture 6-well plate or a Transwell® insert, and provided 24 hours to attach within 
a tissue culture incubator. 
 
2.2.3 – CellTiter AQ one solution cell proliferation assay 
The CellTiter AQ One Solution Cell Proliferation® assay kit detects viable cells 
through its conversion into a formazan product in the presence of active 
mitochondrial succinic dehydrogenase, resulting in a colorimetric change. This 
assay has been used previously for this purpose85. For assessing viability, 20 µl of 
CellTiter AQ reagent was added to 100 µl of cell suspension, under reduced 
lighting. The samples were then incubated in the tissue culture incubator for 1 hour 
before colorimetric analysis (492 nm) using a Bio-Tek KC4 plate reader. Blank 
values (or, samples containing MPs alone) were subtracted from sample readings, 
and, using a standard curve (Appendix 5.1), cell concentration and, therefore, 
percentage viability could be determined. 
 
2.2.4 – Alamar blue assay 
The alamar blue assay was also used to assess viability. This reagent is a REDOX 
indicator that fluoresces in response to the chemical reduction that occurs within 
the growth medium as a cell population metabolises. The main advantage of this 
assay is that it does not infiltrate the cells, and therefore is minimally toxic to 
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living cells, so the assay can be ran on the same batch of cells over various 
timepoints. However, contamination and infection can both lead to a chemical 
reduction, which in turn affects the results86. As the vast majority of cellular 
metabolism occurs via mitochondria, the results from MTT-based assays (such as 
the CellTiter AQ assay) have been found to closely correlate those from Alamar 
blue87,88. 
 
Within a 6-well plate or transwell configuration, StemPro® media was removed 
and replaced with 1 ml StemPro® media containing 100 µl of a 10 × concentration 
alamar blue solution. Cells were left to stand at room temperature for 2 hours, 
before the alamar blue solution was removed and replaced with the media they 
were cultured in previously. The alamar blue solution (100 µl) was transferred to a 
96 well plate before fluorometric analysis (ex 560 nm/ emm 590 nm) was 
performed using a MFX plate reader. Blank values were subtracted from sample 
readings, and, using a standard curve (appendix 5.4), cell concentration and, 
therefore, percentage viability could be determined. 
 
2.2.5 – Staining of viable cells using mitotracker® deep red 
Mitotracker® reagent fluoresces upon binding to active mitochondria. The 
advantage of this stain over the live/dead® solution is the ability for the stain to be 
retained within the cells once they are fixed, allowing one to read all the samples 
together once all the time periods have passed. 
 
To 500 µl of cell suspension, 250 nl of mitotracker® deep red was added, and the 
cells were incubated for 30 minutes in a tissue culture incubator. They were then 
fixed by a 10 minute incubation with 3.7 % (w/v) paraformaldehyde in an 
incubator. 
 
2.2.6 – Flow cytometry analysis 
Cell suspensions were analysed using a Beckman Coulter Cytomics FC500 flow 
cytometer (High Wycombe, UK). Fluorescence emission was collected with 
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interference bandpass filter sets for the spectral regions of 530 ± 30 nm (calcein) 
and 630 ± 22 nm (ethidium homodimer and Mitotracker Deep Red). Isoton II® 
diluent (Beckman Coulter, High Wycombe, UK) was used as sheath fluid, and 
typical flow rates were 60 µl/min, producing between 200 and 1000 events/sec. 
Forward scatter and side scatter data were also collected and cross-referenced with 
the fluorescence data. Data were analysed using Windows Multiple Document 
Interface for flow cytometry (WinMDI) software (Scripps Institute, CA). 
 
Percentage viability was determined by dividing the number of viable events 
(either the events fluorescing at 530 nm when the Live/Dead stain was used, or the 
events within the gated region when the Mitotracker® stain was used) by the total 
number of events that occurred within the control. Using this methods allows one 
to take into account the number of cells that may have lysed and therefore not 
produced an event through the flow cytometer. However, this method does assume 
that no cells lysed within the control group. 
 
2.2.7 – Preparation of zeolite 
The zeolite granules were separated from residual zeolite powder through 
decantation in distilled water, retaining the zeolite granules (sediment). The 
decantation process is repeated at least 5 times in order to ensure all powder is 
removed. The particles were then dried overnight, using a freeze-drier, to remove 
residual moisture. The granules were then weighed into separate 2 or 4 g batches 
and autoclaved at 121°C at 1 bar for 1 hour. 
 
2.2.8 – Glucose concentration determination 
Glucose concentration was determined using a glucose oxidase (GO) assay. This 
assay works by specifically catalyzing the production of hydrogen peroxide from 
glucose, using glucose oxidase. This hydrogen peroxide then oxidises o-
dianisidine, causing the colorimetric change. Recently prepared GO reagent 
(appendix 2.4) (200 µl) was added to 100 µl of sample solution, and incubated at 
37 ºC for 30 minutes, before colorimetric analysis (540 nm) using a Bio-Tek KC4 
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plate reader. Blank values were subtracted from sample readings, and, using a 
standard curve (appendix 5.6), the concentration of glucose could be determined. 
 
2.2.9 – Total protein concentration determination 
Total protein concentration was determined using the Bradford assay (Chapter 3) 
and the Coomassie Plus assay. Both assays work on a similar principle; the 
reagents are able to form a blue complex upon binding to the hydrophobic pockets 
of the protein’s tertiary structure. Few substances interfere with the production of 
the signal89. The Bradford assay was performed simply by the addition of 250 µl of 
Bradford reagent, incubating, at room temperature for 5 minutes, before 
colorimetric analysis (595 nm) using a Bio-Tek KC4 plate reader. Blank values 
were subtracted from sample readings, and, using a standard curve (Appendix 5.3), 
the concentration of total protein could be determined. 
 
The Coomassie assay works by the same principle as the Bradford assay, but has 
the added advantages that the standard curve produced is more linear, and the 
variability of signal after protein interaction is half that of the standard Bradford 
assay (due to the assay’s ability to bind to amino acids other than arginine with a 
greater affinity). Coomassie Plus reagent (300 µl) was added to 10 µl of PBS 
sample, shaken on a plate-shaker for 30 seconds and left to stand at room 
temperature for 10 minutes, before colorimetric analysis (595 nm) using a Bio-Tek 
KC4 plate reader. Blank values were subtracted from sample readings, and, using 
a standard curve (appendix 5.5), the concentration of total protein could be 
determined. 
 
2.2.10 - Statistical analysis 
Data sets were tested for normality and subsequent tests of comparisons were 
chosen appropriately. For simple paired comparisons, the student -test, was 
utilised and expressed as mean ± standard error of the mean (SEM). For normally 
distributed multiple data comparisons, a one-way ANOVA test was utilised and 
expressed as mean ± SEM. Whenever the statistical significance between control 
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and treated samples were evaluated at a 95 % confidence level (< 0.05) or, at a 
99 % confidence level ( < 0.01), the data set would be considered to be 
statistically significant and represented with a (*) or a (**) respectively. 
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3.1 - Introduction 
As discussed in 1.4.2, little is known as to whether the viability and characteristics 
of the delivered cell are affected by the delivery process itself68,69. In this chapter, 
the effect on mMSC viability and apoptosis are described after they were drawn up 
into a syringe, left within the syringe for periods of up to two days, and then 
ejected. Cell viability whilst left within the syringe chamber were compared to the 
viability when the cells were instead left within an eppendorf, either under ambient 
temperature, or 4 °C, in order to provide information regarding how cells should 
be stored prior to an operation. Characteristics important to the functionality of 
mMSCs, such as their ability to spread onto a favourable surface and their 
proliferative ability, are also discussed here. 
 
The parameters regarding how the cells are manipulated, such as ejection rate, 
needle gauge and cell concentration, were based on how the neuronal cells were 
handled by Bible and co-workers;90 this is a paper showing an improvement in 
cerebral recovery after neuronal cells were directly injected into an ischaemic 
brain region of a rat stroke model.  
 
As discussed in depth within the general introduction, mesenchymal stem cell 
therapies have the potential to treat a vast array of disease states. For this reason, 
primary murine mesenchymal stem cells were chosen for this study. 
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The effectiveness of the antioxidant 
-acetyl cysteine in this study was also based 
on the use of the antioxidant in the 
 studies described by Bible 90. 0-
acetyl cysteine is thiol-containing compound that has been shown to have an anti-
apoptotic effect through a direct mechanism involving the reduction of reactive 
oxygen intermediates, and by stimulating the synthesis of glutathione, which, in 
turn, mediates apoptosis91 (figure 3.1). 
 
The mMSCs used in this experiment are anchorage-dependent. Studies have 
shown that following a prolonged period of detachment after trypsinisation has a 
negative effect on cell viability and increases the level of apoptotic activation via 
surface integrin signaling pathways92. To test this hypothesis, cells were seeded 
onto microparticles (MPs) composed of poly(lactic--glycolic acid) (PLGA), and 
the viability of the seeded cells were compared to a single cell suspension post-
ejection. Previous work has shown that seeding cells onto pre-treated PLGA 
surfaces does not affect the viability of the cells compared to tissue-culture 
plastic90. Moreover, PLGA has an established history of showing biocompatible 
characteristics93, allowing one to deliver the particles with the cells to the host. If 
the hypothesis was correct, one could envision the use of PLGA MPs not only to 
deliver important factors to the cells to aid host engraftment93, prevent the 
clearance of the cells and provide a favourable environment to proliferate in94, but 
MPs may also be used to improve the viability of the cells during delivery. 
 
3.2 – Materials and methods 
3.2.1 – Microparticle fabrication 
PLGA MPs were fabricated using a single oil-in-water (O/W) emulsion method, 
and optimised for the production of particles with a diameter of between 50 and 
100 µm. PLGA was dissolved in dichloromethane (DCM) at room temperature, 
overnight. Freshly prepared 0.3 % (w/v) polyvinyl alcohol (PVA) solution was 
slowly added to the vial before the solution was emulsified using a vortex mixer. 
This emulsion was then immediately poured into an 0.3 % PVA hardening bath 
and stirred constantly for at least 24 hours, within a fume hood, to allow the  
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Figure 3.1. Chemical structure of -acetyl cysteine 
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 solvent to evaporate. The solidified MPs were then washed with distilled water 
and harvested via vacuum filtration. After drying the MPs, they were sieved and 
separated using a Retsch AS200 sieve shaker. MPs were stored in individual 
vacuum sealed packets at 4 °C. 
 
3.2.2 – Surface treatment via plasma polymerisation 
MP surface chemistry was modified using a plasma polymerised allylamine 
(ppAAm) deposition technique, using an in-house plasma reactor, as previously 
described95. The plasma reactor consists of a T-shaped borosilicate chamber, 
enclosed within stainless steel endplates, and sealed with Viton O-rings. Plasma 
formation was initiated by two external inductivity coupled copper band electrodes 
connected to a 13.56 MHz power source (Coaxial Power Systems Ltd.) and 
matched manually such that the reflected power was < 1 W. Petri-dishes 
containing MPs were placed into an evacuated chamber and etched with 300 
mTorr of oxygen. The MPs were agitated before this was repeated so that a total of 
5 random etching cycles were performed on the MPs. Following this, the chamber 
was then restabilised at 300 mTorr with allylamine vapour. Deposition of 
allylamine onto the MPs was maintained until a layer 0.5 kÅ thick had formed on 
the quartz crystal microbalance positioned opposite the substrates. A total of 5 
ppAAm coatings were performed on each sample, in between agitating the 
particles, to ensure a complete and uniform surface coating. 
 
3.2.3 – Surface treatment via adsorption of ECM proteins 
MPs were sterilized using 70 % (v/v) ethanol on a shaking platform, at room 
temperature. After rinsing in PBS, an additional wash in 1 % (v/v) penicillin-
streptomycin-amphotericin B solution, was performed, followed by another PBS 
wash. 
 
MPs were pre-wetted with serum-free medium for 24 hours in a tissue-culture 
incubator before being coated with fibronectin, using a standard adsorption 
protocol. A 10 µg/ml fibronectin solution are applied to eppendorfs containing 
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MPs, for three hours in a tissue culture incubator. The MPs were agitated at times 
15, 30, 45, 60 and 90 minutes of the incubation period. Unattached fibronectin was 
then removed, and the MPs were washed twice in PBS. 
 
3.2.4 – Seeding mMSCs onto PLGA microparticles and syringe manipulation 
Murine MSCs were isolated and cultured as described in 2.2.1 and 2.2.2 
respectively. After detachment using trypsin (2.2.2), cell counts and viability 
determination to create the correct viable cell concentration were performed using 
the trypan blue (TB) exclusion technique (appendix 4.3). The cells were then spun 
down at 250 g for 4 minutes, supernatant was removed, and cells were re-
suspended in a volume of Hanks Balanced Saline Solution (HBSS) containing 0.5 
% (w/v) carboxymethyl cellulose (a biocompatible viscosity modifier that prevents 
the settling of the particles so that they effectively be drawn up into the syringe) to 
provide a final cell concentration of 5×107 cells/ml. The cell suspension was either 
added to pre-coated PLGA MPs and incubated in a tissue culture incubator for 1 
hour, gently manually agitating every 15 minutes (seeded cells), or drawn up 
directly into a syringe with a 22 gauge needle (internal diameter 394 µm, appendix 
6) attached at a rate of ~30 µl/min and left to stand for pre-defined time periods at 
room temperature (unseeded cells) (a wider needle gauge was used here, compared 
to the other experiments within this study because the MP suspension could not be 
effectively drawn up into a narrower bore). Ten µl samples of both seeded cells 
and unseeded cells were processed to provide a control. Seeded cells were drawn 
up into a similar syringe and left to stand for pre-defined time periods at room 
temperature. The cell suspensions were ejected at the controlled rate of 5 µl/min 
into full media, as shown in figure 3.2. Samples were then analysed for viability 
using the CellTiter AQ One Solution assay as described in 2.2.3. 
 
A preliminary experiment was carried out to determine the percentage of cells that 
attached to the microparticles and to identify the optimum particle to cell ratio. A 
ratio of 15 cells per microparticle was found to have to best seeding efficiency; 90 
% of the cells attached to the microparticles, as determined using the CellTiter AQ  
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Figure 3.2. Experimental setup of syringes on pump. A general view of the 
apparatus (A), as well as focused side (B) and top (C) views of the syringes are 
provided. The Harvard® PHD 2000 syringe pump was sterilised using 70 % 
industrial methylated spirit and placed within a class II safety cabinet. Luer-
lock needles of various gauges were attached to Hamilton 1701LT syringes. 
Ten µl of cell suspension was then drawn up into the needle and syringe before 
placing the syringes on the syringe pump. Eppendorfs containing 500 µl were 
then taped to the end of the needle to ensure no cell suspension was lost during 
ejection. Programming of syringe diameter allowed ejection to occur at the 
required rate determined by µl/min, rather than mm/min. 
A 
B 
C 
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 One Solution assay as described in 2.2.3(data not shown). Taking this percentage 
attachment allowed one to ensure that the same number of cells were being 
analysed when comparing the cells seeded to the MPs to the unseeded cells. 
 
3.2.5 - Syringe manipulation of the cell suspension 
After the mMSCs were detached using trypsin (2.2.2), cell counts and viability 
determination to create the correct cell concentration were performed using the TB 
exclusion technique (appendix 4.3). The cells were then spun down at 250 g for 4 
minutes, supernatant was removed, and cells were re-suspended in a volume of 
HBSS or HBSS with 60 mM 
-acetyl cysteine (nAC), to provide a final cell 
concentration of 5×107 cells/ml. Ten µl samples of this final concentration were 
processed to provide a control. Samples suspensions were either drawn up into the 
syringe, with a 26s gauge needle attached (internal diameter 114 µm, appendix 6) 
at a rate of ~30 µl/min and left to stand for pre-defined time periods at room 
temperature, or transferred into sterile 500 µl eppendorfs and left to stand at either 
room temperature, or 4 °C. They were then either ejected at the controlled rate of 
either 5 µl/min or 1 µl/min, into 500 µl of full media (figure 3.2), or added to 500 
µl of full media directly (for eppendorf samples). 
 
3.2.6 - Cell viability and proliferation 
For assessing viability, after the cells were manipulated as described in 3.2.4 and 
3.2.5, the CellTiter AQ One Solution Cell Proliferation assay was used as 
described in 2.2.3. 
 
For the cell proliferation study, mMSCs were ejected into the well of a 6-well-
plate containing 2 ml of complete mMSC medium. After 24 and 48 hours, the cells 
are detached from the well plate surface as described in 2.4, centrifuged and re-
suspended in 500 µl complete medium. 100 µl of this suspension was then 
analysed using the CellTiter AQ assay as described in 2.2.3. 
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3.2.7 - Caspase-3 activity assay 
Programmed cell death was assessed using the commercially available CaspACE® 
Assay system (Promega, Southampton, UK). The apoptotic index of the cell line is 
defined by the ability of caspase-3 to cleave an Ac-(aspartate-glutamate-valine-
asparate)-p-nitroaniline substrate and release the detectable chromophore, p-
nitroaniline (pNA). Caspase-3 is a key protease up-regulated in the vast majority 
of apoptotic pathways, though cannot account for all apoptotic pathways96.  
 
The cells experienced the appropriate culture conditions (3.2.5) before being 
transferred to a fresh eppendorf containing 10 µl HBSS and being treated to 3 
freeze-thaw cycles to induce cell lysis. Cell debris was removed by centrifugation 
at 15,000 g for 20 minutes, at 4 °C. Clarified supernatant samples were incubated 
with the appropriate assay mixture, in a tissue culture incubator, for 4 hours before 
colorimetric analysis (405 nm) using a Bio-Tek KC4 plate reader. Apoptosis in the 
positive controls was induced using 1 µM of the protein kinase inhibitor 
staurosporine, whereas the irreversible and cell-permeable pan-caspace inhibitor, 
Z-VAD-FMK, was added (50 mM final concentration) to the negative control 
together with the staurosporine. The negative control values were subtracted from 
sample readings, and, using a standard curve (Appendix 5.2), the concentration of 
-nitroaniline could be determined. 
 
3.2.8 - Protein concentration 
Protein concentration determination was performed in order to normalise the 
concentration of caspase-3 with respect to the level of total protein. Total protein 
was determined using the Bradford assay, as described in 2.2.9.  
 
3.2.9 - Cell attachment and spreading assay 
Cell attachment and spreading was assessed using the dual May-Grunwald and 
Giemsa staining technique for the cytoplasm and nucleus, respectively. After 
manipulating the mMSCs as described in 3.2.5, they were seeded on tissue-culture 
plastic at a density of 630 cells/mm2. After allowing 2 hours for cells to attach and 
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spread within a tissue culture incubator, they were fixed with 3.7 % (w/v) 
paraformaldehyde, permeabilised by the addition of 0.1 % (v/v) Triton X-100, 
before staining with May-Grunwald (0.25 % (w/v) in methanol) and Giemsa stains 
(0.4 % (w/v) in methanol). Cells were then viewed at 200 × magnification using a 
Leica DM-IRB/E inverted microscope. Ten separate fixed-size, non-overlapping, 
random fields per sample were photographed with the in-built digital camera and 
the images subsequently analysed using Volocity® image software. Spread cells 
were distinguished and characterised based upon the presence of a clear halo of 
cytoplasm surrounding their nucleus, following the rearrangement within the actin 
skeleton, as previously described97. 
 
3.3 – Results 
3.3.1 - Cell viability 
Figure 3.3 documents the cell viability data following sample manipulation and 
assessment using the MTS assay. Regardless of the ejection rate, cell viability is 
significantly reduced from the 100 % control values, immediately, following 
ejection from the syringe needle (i.e. at the 0 hour time-point) ( < 0.05). No 
noteworthy differences in viability were observed when the ejection rate was 
altered or when nAC was present. 
 
This observation is significantly different compared with the eppendorf system; a 
relatively smaller decrease in viability occurred over the 24 hour period ( < 0.01). 
After 4 hours, the cells stored at 4 °C decrease in viability at a significantly 
quicker rate compared to those left at room temperature, with less than half of the 
cells viable at 4 °C compared to 68 % at room temperature. 
 
Figure 3.4 compares the viability of cells seeded onto PLGA MPs against single 
cell suspension post-ejection. Seeded cells onto MPs showed a significant decrease  
in viability compared to single cell suspension after 2 to 8 hours within the syringe 
chamber compared to the equivalent single cell suspension. 
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Figure 3.3. Viability of mMSCs following specific periods within either a 
syringe chamber (solid lines) or eppendorf (dashed lines). Cells within the 
syringe chamber were ejected at 5 µl/min ( ), 1µl/min ( ) or 1 µl/min in the 
presence of -acetyl cysteine ( ). Cell within the eppendorf were kept at 
either room temperature (n) or at 4 °C (). Determined using the CellTiter 
AQ assay system (Promega). Results are the mean values ± SEM from 3 
independent experiments, each having triplicate samples. Sample data were 
normalised against control values of 100 %. Superimposed graph focuses on the 
first 2 hours within either the syringe or eppendorf. 
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Figure 3.4. Viability of mMSCs following specific periods within a syringe 
chamber and ejection. Cells were drawn up into the syringe chamber either 
seeded onto PLGA microparticles ( ) or as a single cell suspension ( ). 
Determined using the CellTiter AQ assay system (Promega). Sample data were 
normalised against control values of 100 %. Superimposed graph represents a 
separate study focusing on the first 4 hours within the syringe. 
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 Unlike what is observed in figure 3.3, there was no significant decrease in 
viability when either seeded cells or single mMSC suspension were ejected from 
syringes with a 22 gauge (394 µm diameter) needle attached. 
 
3.3.2 - Apoptosis 
Figure 3.5 shows an increase of caspace-3 activity with increased time as the cells 
were within the syringe chamber. On comparing the caspase-3 activity levels 
between the 5 µl/min and 1 µl/min ejection rates, the activity levels were 
significantly greater (at the 2 hour time-point onwards) for the higher ejection rate 
sample (< 0.05), though this trend does not continue after 24 hours within the 
syringe. No significant differences were demonstrated between the 1 µl/min 
ejection rate samples supplemented with and without 60 mM nAC (< 0.05) at all 
the time-points. 
 
3.3.3 - Cell attachment and spreading 
Representative images of attached and spread cells are presented in table 3.1 with 
figures 3.6 and 3.7 showing the capability of mMSCs to re-attach and spread on 
tissue culture surfaces, respectively, following stagnant periods within the syringe 
chamber. There was a significant reduction (< 0.05) in the number of attaching 
mMSCs following the immediate ejection (0 hour time-point) and this decrease is 
maintained with increasing stagnant periods within the syringe chamber for both 
ejection rates ( < 0.01). The presence of 60 mM nAC caused a significant 
decrease in the number of cells attaching when the cells were subjected to 2 hours 
within the syringe ( < 0.01) as an almost complete loss of attachment was 
achieved. A similar end point was only reached following 4 hours within the 
syringe in samples ejected at 1 µl/min without nAC. In contrast, at the 5 µl/min 
ejection rate, over 30 % of the mMSCs were still able to attach after being within 
the syringe chamber for 4 hours. 
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Figure 3.5. Caspase-3 activity levels of mMSCs following specific periods 
within the syringe chamber and ejection at 5 µl/min (□), 1 µl/min ( ) or 
1µl/min in the presence of -acetyl cysteine ( ).  Determined using the 
CaspACE assay system (Promega). Results are the mean values ± SEM from 3 
independent experiments, each having triplicate samples. Sample data were 
normalised against control values. 
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Table 3.1. Attachment and spreading of mMSCs following specific periods 
within the syringe chamber and ejection at 5 µl/min, 1 µl/min and 1 µl/min in 
the presence of -acetyl cysteine. Following syringe manipulations, cells were re-
cultured on tissue culture plastic, and placed within a tissue culture incubator for 2 
hours to all the cells to attach. The cells were then fixed using 3.7 % (w/v) 
paraformaldehyde and stained with May-Grunwald and Giemsa before being 
viewed at × 20 magnification. 10 separate random fields per sample were imaged, 
showing examples of (a) spread cells (b) attached but unspread cells and (c) cell 
debris. nAC; 
-acetyl cysteine. 
a 
b 
c 
200mm 
2
0
0
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m
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Figure 3.6. Attachment of mMSCs following specific periods within the 
syringe chamber and ejection at the rate of 5 µl/min ( ), 1 µl/min ( ) and 1 
µl/min with 60 mM -acetyl cysteine ( ). Ten images were taken from each of 
three samples. Sample data were normalised against control. Asterisks represent 
the level of significance compared to control sample (* where < 0.05, ** where 
< 0.01). 
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Figure 3.7. Extent of spreading of mMSCs following specific periods within 
the syringe chamber and ejection at a rate of 5 µl/min ( ), 1 µl/min ( ) and 1 
µl/min with 60 mM -acetyl cysteine ( ). Ten images were taken from each of 
three samples. Sample data were normalised against control. Asterisks represent 
the level of significance compared to control sample (* where < 0.05, ** where 
< 0.01). 
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Although the attached mMSCs number decreased as the time period within the 
syringe chamber increased, the ! of the cell spreading appeared to be 
unaffected based on the extent of area of spreading per cell (figure 3.7). A high 
total surface area per cell is characteristic of a positive degree of spreading. A 
significant decrease in spreading did not occur until after 30 minutes within the 
syringe chamber. After 4 hours, the bar representing the cell suspension containing 
nAC is not present, as, at this time-point, no cells were attached to assess the 
spreading of. 
 
A characteristic with regard to cell spreading that is noticeable in table 3.1, but is 
not quantified in figure 3.6 or 3.7, is the apparent increase in cell debris when the 
cells are left within the syringe chamber for increasing periods of time. There was 
a visible increase in cell debris when the cells are drawn up into and immediately 
expelled, compared to control. 
 
3.3.4 - Cell proliferation 
The proliferative ability of the mMSCs that were still viable following time within 
the syringe chamber and ejection at 5 µl/min were not significantly affected (< 
0.05) until after 8 hours compared against control (figure 3.8) (the proliferation 
trend for cells left within the syringe chamber for 24 hours was not fully plotted, as 
the negative cell concentrations obtained could not be plotted on a logarithmic 
scale). On increasing the time period within the syringe chamber, the doubling 
time (td) of the mMSCs increased, but not significantly (table 3.2). 
 
3.4 – Discussion 
The overall aim of this study was to investigate the cellular response of mMSCs 
following their manipulation and varying time period within a syringe-based 
delivery system. “Clinical success” of current cell therapy applications is often 
based upon the analysis of post-operative response i.e. restoration of function, 
tissue integration and/or cell localization63. However, for the majority of these 
cases, cells are usually only tracked (using a variety of dyes or contrasting  
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Figure 3.8. Proliferative count of mMSCs under favourable conditions 
following specific periods within the syringe chamber and ejection at 5 
µl/min. Cells were left to stand within the delivery device for 0 (□), 2 (▲), 4 
(×), 8 (+) and 24 hours (-) before being re-cultured on tissue culture plastic. 
Proliferation rates were determined using the CellTiter AQ assay system 
(Promega). Results are the mean values ± SEM from 2 independent experiments, 
each having triplicate samples. Sample data were normalised against control ( ) 
and plotted on an exponential axis. 
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Length of Incubation 
within syringe (h)  
Td (h) 
Control 16.0 
0 15.1 
2 16.5 
4 17.1 
8 17.1 
24 N/A 
 
Table 3.2 Mean doubling rates (Td) of mMSCs following specific periods of 
neglect and post-ejection at 5 µl/min. 
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agents)65,66,67 for a brief period post-injection and there have been few recent 
studies investigating the actual effect of passing a cell suspension through a 
needle-based delivery device. 
 
This study could be considered as a development of work published by 
Kondziolka and co-workers; they assessed the viability of neuronal cells passed 
through a 25 gauge needle and cannula using a simple trypan blue exclusion 
method69. Even though this work outlined a potential issue with delivering cells 
parenterally by showing a significant decrease in viability post-ejection, the 
method used to analyse viability has been reported to be inaccurate, due to the low 
number of cells analysed98. Furthermore, no assessment of whether the remaining 
viable cells post-ejection were functional. For these reasons, further investigation 
was required. 
 
An informative finding from this study was that there was a significant (albeit 
small) decrease in viability when mMSCs were immediately ejected once drawn 
up into a syringe attached. This suggests that the shear stresses the cells experience 
as they are drawn through the narrow bore have a key detrimental effect on cell 
integrity. This is supported by the lack of significant viability decrease when the 
cells were drawn through a wider bore, or placed within an eppendorf. It could be 
argued that the decrease in viability could be attributed to a reduction of total cell 
number due to the volumetric loss of cell suspension in coating the internal 
surfaces of the needle and delivery device. However, this seems unlikely, as, if this 
were the case, one would expect to see the same or greater decrease in viability as 
the cells were passed through the wider bore needles (as the internal surface area 
of a wider bore would be greater). Moreover, if cells were lost in coating the 
syringe surface, this may be an issue that researchers would like to quantify when 
carrying out clinical studies. 
 
Within the eppendorf study, cells were kept at either room temperature or 4 °C, in 
order to investigate whether temporary storage at reduced temperature would 
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prolong cell survival if a clinical procedure were delayed. A similar study to this 
has been carried out using similar marrow stromal cells (though human-derived), 
with the aim of analysing the effect of short-term cell transportation on viability81.  
This study was also similar to the one described here in that they also compared 
storage at room temperature to storage at 4 °C. Their results showed that storage of 
low passage (passage 3) hMSCs at 4 °C, at a concentration of 2 × 107 cells/ml 
(similar to the concentration of 5 × 107 cells/ml used in eppendorf study), had a 
similar effect on cell viability; after 24 hours of storage, they reported a loss of 
viability of 40 %, compared to the 50 % decrease shown in figure 3.3. This 
comparison suggests that the passage number and the species the cells are derived 
from have little influence on their tolerance to storage under such conditions. 
 
 As documented by our experimental results, incubation at a reduced temperature 
after 4 hours decreased cell viability compared to room temperature. Such an 
observation has been reported by Ma and co-workers99 who analysed the effect of 
the preservation of human haemopoietic stem cells at 4 °C on viability. The study 
by Lane   also showed no significant difference between storage at 4 °C 
compared to storage at room temperature81. 
 
When comparing a single mMSC suspension against cells seeded onto PLGA MPs 
(figure 3.4), the expected improvement in viability in the seeded cells did not 
occur, and, on the contrary, there was a significant decrease in viability within the 
seeded cells at some time-points. Compared to the detachment of mMSCs from 
tissue culture plastic, using trypsin that cleaves their surface-attachment proteins, 
the MPs were thought to allow the attachment proteins to re-grow and attach to a 
surface under favourable conditions before delivery. However, one issue that was 
not foreseen regarding MPs when delivering a highly concentrated cell suspension 
was the increase of solid mass that could increase the shear forces experienced by 
the cells whilst passing through the narrow bore. The seeding was found to be 15 
cells per MP on average; if the amount of seeding was increased per MP, the 
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number of MPs required could be reduced and, in theory the shear stresses could 
be reduced. This may, in turn, improve cell viability. 
 
With regard to the amount of time the mMSCs were within the syringe chamber, it 
was found that the longer this time period, the lower the viability of the cells 
following recovery in culture media. Such an effect may be attributed to a variety 
of culture conditions known to induce apoptosis, i.e. aeration levels, nutrient 
deficiency, toxic metabolite build-up and cell signaling92,100,101,102. However, there 
was little change in viability in the eppendorf system despite the cells being 
exposed to similar stresses. It is also plausible that the passage of cells through an 
extremely narrow channel and/or at a high rate may induce apoptosis- initiating the 
controlled cell death pathway and also contributing to the downstream decrease in 
viability state upon the point of ejection and analysis. 
 
It has also been demonstrated that nAC provided no significant beneficial effects 
in cell viability compared to the non-supplemented control. Furthermore, no 
significant changes were detected in the corresponding caspase-3 activity ( < 
0.05). Such an observation was found to be of contrast to the findings reported by 
Muscari and co-workers who specifically demonstrated an inhibition of apoptosis 
in rat MSCs103. Although other researchers have also demonstrated a similar effect 
of nAC supplementation (via the stimulation of glutathione synthesis and 
reduction of hydroxyl radicals), this attribute is very dependent on the cell-line 
involved104,105,106,107,108. It is also possible that, due to caspase activation being a 
later event within the apoptotic cascade, the beneficial effects of nAC were not 
seen because the control was within an early, and therefore undetectable state of 
apoptosis. This could be assessed by detecting phosphatidylserine exposure on the 
outer surface of the cell membrane (which is classed as an earlier apoptotic event), 
using annexin V109.   
 
Referring to figures 3.7 and 3.8, it is seen that the majority of cells that survive the 
syringe-based manipulations, after a short period of time within the syringe, tend 
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to function with regard to their ability to spread and proliferate. As cells would 
need to attach before proliferating110,111,112, the fact that cells that were within the 
syringe chamber for up to 8 hours were able to proliferate at a rate similar to 
control suggests that a greater number of cells would have attached to the tissue 
culture substrate than observed in figure 3.6 if provided with a lengthier time 
period in which to attach. However, this attachment time needed to be low in order 
to ensure that the cells did not proliferate, which would have led to an increase in 
the recorded attached number. 
 
As such, it may be suggested that the manipulation of mMSCs within a needle-
based delivery device partially induces a delay on cell recovery. This delay may be 
required for the initiation of basic cellular repair mechanisms and, consequently, 
reduce the degree of cell attachment, spreading and proliferation on a culture 
substrate. Such behaviour is characteristic of apoptosis and, as such, these physical 
insults may cause the appropriate cellular mechanisms and energy diversion to 
initiate the controlled death programme. At greater shear stress levels (longer time 
periods within the syringe), these negative effects become more pronounced and, 
in situations of extended stress, cell death via membrane lysis occurs- explaining 
the presence of the cell debris, shown in table 3.1. Furthermore, in the presence of 
nAC, there was a compounded negative effect on the mMSCs recovery and 
downstream abilities in the majority of culture conditions. 
 
3.5 – Conclusions 
In summary, it has been shown that the manipulation of mMSCs within a syringe-
based delivery device sensitises the cells by inducing significant effects on their 
cellular response namely, a reduction in cell viability, attachment and spreading 
characteristics and, to a lesser extent, proliferation rates. Moreover, the greater the 
cellular insult (i.e. a longer time period within the syringe chamber), the more 
pronounced and significant the effects on the recoverability of the cells. As such, 
evidence is presented suggesting that the manipulation process may not only 
induce cell death via necrosis but, also induce apoptosis and that this programmed 
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death cycle cannot be prevented by the addition of the anti-oxidising agent, nAC, 
nor the provision of a suitable attachment surface. Thus, for potential clinical cell 
therapy applications, it is important to consider the preparation and manipulation 
of the cell suspension and also to account for the viability and cellular response of 
these cells post-ejection. 
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4.1 - Introduction 
The results from Chapter 3 raise questions regarding how altering the parameters 
related to the syringe-based manipulations may affect cell viability. Three key 
questions raised are:- 
- How does the needle bore diameter affect viability? Previous results suggest a 
key difference in viability when cells are drawn up and immediately ejected 
from a 22 gauge to a 26s gauge. Further analysis of these needle gauges was 
performed, incorporating studies using a 25 gauge needle also (corresponding 
internal diameters for these needle gauges can be found in appendix 6). 
- How does varying the concentration of nAC affect viability? The 
concentration of nAC used in chapter 3 was based on the concentration used 
in Bible 90, but the rationale behind why this concentration was used was 
unclear. For this reason, various nAC concentrations were compared, with the 
aim of finding an optimum concentration. 
- How does varying the ejection rate affect viability? There were no noteworthy 
differences between cells ejected at 5 µl/min compared to 1 µl/min, but both 
were relatively slow rates. The effects of the quicker ejection rate of 20 µl/min 
was assessed.  
 
Flow cytometric analysis could be argued to be a more accurate method to use to 
determine a level of viability. This is because metabolic assays, such as the one 
Chapter 4   Flow cytometric analysis of mesenchymal stem cell viability post-ejection 
   
  58 
used in Chapter 3, assesses viability through detecting mitochondrial activity, and 
assumes that each viable cell has a constant level of mitochondrial activity, 
therefore a decrease in signal from such an assay could be caused by not only a 
decrease in viable cell number, but also a decrease in metabolic activity. However, 
flow cytometry scans a sub-population of cells and provides a discrete number of 
viable cells, based on the characteristics of the dye used, so, assuming that the 
signal of a cell with low metabolic activity is detectable, the level of viability 
within a cell population determined using flow cytometry should not be affected 
by metabolic rate. Furthermore, flow cytometry provides information with regard 
to cell size and cell granularity, which can be related to whether a cell is 
undergoing apoptosis, and so provides additional information useful to this study. 
For the reasons above, it was decided that flow cytometry would be used as an 
additional analytical tool to assess the effect of syringe-based manipulations on 
cell viability. 
 
4.2 – Materials and methods 
4.2.1 - The effect of needle gauge and ejection rate 
Murine MSCs were isolated and cultured as described in 2.2.1 and 2.2.2 
respectively. After cell detachment using trypsin (2.2.2), cell counts and viability 
determination to create the correct cell concentration were performed using the 
trypan blue (TB) exclusion technique (appendix 4.3).  The cells were then pelleted 
at 250 g for 4 minutes, supernatant removed, and re-suspended in HBSS to provide 
a final cell concentration of 5×107 cells/ml. Sample cell suspensions were then 
drawn up into syringes with either a 26s, 25 or 22 gauge needle (appendix 6) 
attached and ejected at a rate of either 20, 5 or 1 µl/min, into 500 µl of complete 
media, as shown in figure 3.2. Following the expulsion, samples were incubated 
for 30 minutes at room temperature in 1 ml Live/Dead® working solution, 
protected from light, before being analysed using flow cytometry as described in 
2.2.5. 
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The Live/Dead® solution consists of calcein AM, which yields green fluorescence 
upon cleavage by active cell esterase, detecting viable cells, and a membrane 
impermanent ethidium homodimer, that fluoresces red after binding to nucleic 
acids. 
 
4.2.2 - The effect of 
-acetyl cysteine concentration 
After mMSC detachment using trypsin (2.2.2), cell counts and viability 
determination to create the correct cell concentration were performed using the TB 
exclusion technique (appendix 4.3).  The cells were then spun down at 250 g for 4 
minutes before the supernatant was removed and the cells were re-suspended 
(5×107 cells/ml) in HBSS or HBSS supplemented with 20, 60 or 100 mM 
-acetyl 
cysteine (nAC). These cell suspensions were then drawn up into syringes, left to 
stand for 2 hours (in order to induce partial cell death, so that the positive 
influences of nAC could be determined) before being ejected, via a 26s gauge 
needle, at 1 µl/min into 500 µl of complete media. Following the expulsion, 
samples were incubated for 30 minutes at room temperature in 1 ml Live/Dead® 
working solution, protected from light, before being analysed using flow 
cytometry as described in 2.2.5. 
 
4.2.3 - The effect of sustained incubation 
After mMSC detachment using trypsin (2.2.2), cell counts and viability 
determination to create the correct cell concentration were performed using the TB 
exclusion technique (appendix 4.3).  The cells were then spun down at 250 g for 4 
minutes, supernatant was removed, and cells were re-suspended in a volume of 
HBSS or HBSS with 60 mM 
-acetyl cysteine (nAC), to provide a final cell 
concentration of 5×107 cells/ml. Samples suspensions were then drawn up into the 
syringe and left to stand for pre-defined time periods at room temperature before 
being ejected through a 26s gauge (internal diameter 114 µm, appendix 6) needle 
into 500 µl of mMSC media. These cells were then stained with mitotracker® deep 
red, as described in 2.2.5, before being analysed using flow cytometry as described 
in 2.2.6. 
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In a separate study, the concentrated cell suspension was separated into 10 µl 
aliquots, then left to stand for pre-defined time periods at either room temperature 
(18-20 °C) or 4 °C. Samples were then incubated with a mitotracker® solution 
(2.2.4), before again being analysed using flow cytometry (2.2.5). 
 
4.3 – Results 
4.3.1 - The effect of needle gauge and ejection rate 
Table 4.1 and figure 4.1 summarise the flow cytometric analyses of cells once 
ejected at different ejection rates and through a variety of needle gauges. On 
comparing cell size and cell granularity, two distinct sub-populations are visible; 
large, clear cells (the events near to the x axis) and small, granular cells (the events 
near the y axis). These sub-populations correspond closely with the fluorescence 
data obtained; green fluorescent events correlated with the large, clear cells, and 
red fluorescent events were generally the small and granular cells.  There was a 
visible increase of non-viable cells with the 26s gauge needle attached, as shown 
in table 4.1, but, as shown in figure 4.1, there were significant decreases in 
viability in both the 26s and the 25 needle gauges (< 0.05) compared against 
control. Moreover, a noticeable level of cell debris (detected as events with a very 
low level of forward scatter, and therefore, of a small diameter) was seen with the 
26s needle gauge, though this level of debris could not be quantified in terms of 
cell number (data not shown ). No significant differences were observed between 
the various ejection rates. 
 
4.3.2 - The effect of 
-acetyl cysteine concentration 
In table 4.2, a higher number of non-viable cell events were observed for samples 
left within the syringe chamber for 2 hours before ejection. At both the 20 mM and 
the 60 mM nAC concentrations, an insignificant increase in viability was observed 
compared to the control sample (figure 4.2). When a nAC concentration of 100 
mM was used, all of the cells were found to be non-viable. 
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Table 4.1. Flow cytometry scatter plots comparing mMSC size (x-axis) 
against granularity (y-axis), post-ejection, at different rates through a 
variety of needle gauges. Cells were immediately expelled once drawn up 
into the syringe device. Following the expulsion, samples were incubated for 
30 minutes with Live/Dead® solution (calcein AM/ethidium homodimer) 
according to the manufacturers’ instructions before being analysed using a 
Beckman Coulter Cytomics FC500 flow cytometer (High Wycombe, UK) at 
60 µl/min. Samples were analysed using WinMDI with viable events 
represented in green and non-viable events in red. 
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Figure 4.1. mMSC viability post-ejection, at different rates through a 
variety of needle gauges. Cells were immediately expelled once drawn up to 
into the syringe device at an ejection rate of either 20 ( ) 5 ( ) or 1 ( ) µl/min 
and compared against control ( ). Following the expulsion, samples were 
incubated for 30 minutes with Live/Dead® solution (calcein AM/ethidium 
homodimer) according to the manufacturers’ instructions before being analysed 
using a Beckman Coulter Cytomics FC500 flow cytometer (High Wycombe, 
UK) at 60 µl/min. Results represent mean percentage viability ± SEM. 
Asterisks represent the level of significance compared to control sample (< 
0.05). 
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Table 4.2. Flow cytometry scatter plots comparing mMSC size (x-axis) against 
granularity (y-axis), post-ejection, within a suspension containing various 
concentrations of -acetyl-cysteine. Sample cells were left to stand within the 
syringe chamber for 2 hours before being ejected at 1 µl/min via a 26s gauge 
needle, whilst the control sample was transferred for staining without incubation at 
room temperature or ejection. Samples were incubated for 30 minutes with 
Live/Dead® solution (calcein AM/ethidium homodimer) according to the 
manufacturers’ instructions before being analysed using a Beckman Coulter 
Cytomics FC500 flow cytometer (High Wycombe, UK) at 60 µl/min. Samples 
were analysed using WinMDI with viable cells stained green and non-viable 
stained red. 
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Figure 4.2. mMSC viability post-ejection, within a suspension containing 
various concentrations of -acetyl-cysteine, compared to control. Following 
the expulsion, samples were incubated for 30 minutes with Live/Dead® solution 
(calcein AM/ethidium homodimer) according to the manufacturers’ instructions 
before being analysed using a Beckman Coulter Cytomics FC500 flow 
cytometer (High Wycombe, UK) at 60 µl/min. Results represent mean 
percentage viability ± SEM. Asterisks represent the level of significance 
compared to control sample (< 0.01). 
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4.3.3 - The effect of sustained incubation within the syringe chamber 
Data summarised in table 4.3 and figure 4.3 compare cell diameter to the intensity 
of viable fluorescence for mMSCs following extended periods within a syringe 
chamber following expulsion at different ejection rates. The decrease in 
fluorescent intensity corresponding to the smaller cell-sized population may be 
explained by the fact that (i) smaller cells have less mitochondria and therefore 
have a lower maximum of dye that can be absorbed, or (ii) the cells have 
compartmentalised due to apoptosis and can subsequently absorb no dye. There 
was a rapid decrease in viability with increasing time periods within the syringe 
chamber and, at the 4 hour time-point, the majority of the MSCs were found to be 
non-viable. When comparing the differing ejection rates used, or the presence of 
nAC to without, no noteworthy changes were observed, and this agrees generally 
with the results discussed in Chapter 3. 
 
4.3.4 – The effect of sustained incubation within the eppendorf 
Table 4.4 shows very little change within the scatterplots for all time periods, and 
this is reflected in figure 4.3, which shows only a small decrease in viability over 
the 4 hour period. There was a significant decrease in viability only after 4 hours 
within the eppendorf at both room temperature and 4 °C, compared to control 
(time 0 in figure 4.3) ( < 0.05). 
 
4.4 – Discussion 
Within this investigation, the viability of mMSCs following their ejection through 
three different needle gauges was assessed; 26s, 25 and 22, which have the internal 
diameters of 114, 241 and 394 µm respectively (appendix 6). The selection of an 
appropriate needle gauge used during a cell therapy application is very much 
dependent on clinical parameters, namely the volume of fluid delivered, the size 
and fragility of the target location/organ, the number of cells required for a clinical 
effect etc. As such, various needle gauge sizes have been successfully 
demonstrated for medical applications, ranging from 22 gauge113,114 to 25 
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Table 4.3. Flow cytometry scatter plots comparing mMSC size (x-axis) 
against fluorescent intensity (y-axis) following specific periods within the 
syringe chamber at different ejection rates. At specific timepoints, samples 
were incubated mitotracker® deep red dye according to the manufacturers’ 
instructions before being analysed using a Beckman Coulter Cytomics FC500 
flow cytometer (High Wycombe, UK) at 60 µl/min. Samples were analysed 
using WinMDI with region of interest highlighted by the polygon. nAC; 
-
acetyl cysteine. 
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Table 4.4. Flow cytometry scatter plots comparing mMSC size (x-axis) 
against fluorescent intensity (y-axis) following specific periods within the 
eppendorf at either room temperature or 4 °C. At specific timepoints, 
samples were incubated mitotracker® deep red dye according to the 
manufacturers’ instructions before being analysed using a Beckman Coulter 
Cytomics FC500 flow cytometer (High Wycombe, UK) at 60 µl/min. Samples 
were analysed using WinMDI with region of interest highlighted by the 
polygon. 
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Figure 4.3. Viability of mMSCs following specific periods within either a 
syringe chamber (solid lines) or eppendorf (dashed lines). Cells within the 
syringe chamber were ejected at 5 µl/min ( ), 1 µl/min ( ) or 1 µl/min in 
the presence of -acetyl cysteine ( ). Cell within the eppendorf were kept 
at either room temperature (n) or at 4 °C (). At specific timepoints, 
samples were incubated mitotracker® deep red dye according to the 
manufacturers’ instructions before being analysed using a Beckman Coulter 
Cytomics FC500 flow cytometer (High Wycombe, UK) at 60 µl/min. Samples 
were analysed using WinMDI. Results represent mean percentage viability ± 
SEM. 
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gauge69,115. The narrow 26s gauge was used to minimise the quantity of residual 
suspension within the syringe following ejection. 
 
Herein, we have demonstrated that mMSC viability significantly decreased upon 
immediate ejection from a 26s and a 25 gauge needle, but not following expulsion 
from a 22 gauge needle. This trend was identified for all the ejection rates studied. 
 
As such, it may be speculated that the shear stress experienced during the 
expulsion process was a contributing factor for this reduction of cell viability and 
caused the reduction in cell number via direct cell insult and/or lysis. As shear 
stress is linearly inversely proportional to the area a substance is applied 
through116, it could be deduced that the shear stress that a cell suspension 
experiences through a 26s needle is 12 and 4 times greater than that experienced 
through a 22 and 25 gauge needle respectively (appendix 6). However, when 
considering that, as a liquid moves from a wide bore (the syringe chamber) to a 
narrower bore (needle), the velocity at which the liquid moves increases, this 
would further increase the shear stresses the cells would experience within the 
narrower bores. Table 4.5 shows the shear stress values that a water solution, 
containing no cells, would experience when passing through the needles used in 
this study (26s, 25 and 22 gauge), at the ejection rates used in the study 
(mathematical derivation of the values can be found in appendix 7). When using 
the derived values from table 4.5, the cells would actually experience a shear stress 
that is 81 and 19 times greater than that experienced through a 22 and 25 needle 
respectively.  The influential effect of the needle bore size on cell fate post-
ejection was highlighted by Veraitch  who found that 45 passages through a 
bore of 500 µm diameter were required before a significant decrease in viability 
was observed68 (though the ESCs used in that study are smaller than the MSCs 
used here, and that would affect their results). Furthermore, Glossop and Cartmell 
reported the up-regulation of negative regulators of mitosis following induction 
under a controlled tensile strain and concluded that this increased strain may 
encourage an anti-proliferative transition117. 
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Table 4.5. Shear stress (mPa) experienced by water (without cells) as it is 
passed through needles of various gauges at a variety of ejection rates. 
Mathematical derivation of these shear stress is presented in appendix 7118 
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It is known that a higher ejection rate induces greater shear stresses to a cell 
suspension due to the increases in pressure and frictional forces within the needle. 
When comparing the shear stresses in table 5, it can be seen that there is a direct 
linear relationship between ejection rate and shear stress (i.e. the shear stress the 
cells would experience would be 20 and 5 times greater at ejection rates of 20 
µl/min and 5 µl/min compared to 1 µl/min). However, no significant differences 
could be observed between the different ejection rates investigated here. A 
possible explanation could be based on how the samples were prepared; cells 
samples were loaded directly into the syringe via the needle at ~30 µl/min, which 
was at a higher rate than the highest ejection rate investigated. This loading rate 
was used to mimic the conditions during routine cell-therapy; often the ejection 
rate is controlled and slow in order to ensure minimal inflammation to the delivery 
site, but the loading rate is not controlled. 
 
After finding no significant effect of nAC in improving cell viability or cell 
function in Chapter 3, it was important to explore whether the concentration of 
nAC was either too high or too low to elicit the beneficial effect that nAC has been 
reported to provide in the literature103. Table 4.2 and figure 4.2 show that 
concentrations below and above the 60 mM used in Chapter 3 provided no 
improvement in viability and, instead, a concentration of 100 mM was actually 
found to be toxic to the cells. However, when considering the mechanism by 
which nAC has been reported to provide its anti-apoptotic effect (not only through 
the direct interaction with oxygen-reactive species, but through the activation of 
glutathione)91, one may speculate that nAC was not seen to be effective because an 
insufficient period of exposure to the cells occurred to significantly increase the 
levels of glutathione, and therefore, only the direct effects of nAC were being 
assessed. An effective way to assess this would be to culture the cells in media 
supplemented with nAC for 24 hours before the syringe studies were carried out. 
 
When comparing the results shown in figure 4.3 and tables 4.3 and 4.4 against 
those shown in figure 3.3, it is intriguing to see such a level of agreement between 
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the different methods; they all show (i) a significant decrease in viability upon 
immediate ejection through the bore of a 25 gauge bore or narrower, (ii) a decrease 
in viability when cells are left within the syringe for increasing time periods 
compared to when left within an eppendorf, and (iii) minimal effects of nAC or 
ejection rate on cell viability. This suggests that cell death occurs via a pathway 
that initiates a whole host of alterations that can be detected. For example, there is 
a clear link between the changes in cell morphology and cell viability, as when 
cells undergo apoptosis, they shrink as they compartmentalise and become more 
granular as their cell membrane condenses92. However, there is a discrepancy in 
the rate of cell death within the syringe chamber, especially after one hour, as the 
Mitotracker detects a much quicker decrease in viability compared to the Celltiter 
colorimetric assay; reasons for this are unclear.  
 
4.5 - Conclusions 
Flow cytometric analysis confirms the results shown in Chapter 3; a similar 
decrease in viability occurred when mMSCs were left within the syringe chamber 
for prolonged lengths of time, and this viability decrease was more rapid when 
compared to cells left within an eppendorf. Increasing the ejection rate to 20 
µl/min did not significantly decrease cell viability, yet increasing the needle gauge 
diameter to a 22g did significantly improve viability, suggesting that the shear 
stresses the cells experience through the syringe have a key impact on cell fate. 
Analysis of varying nAC concentrations on cell viability suggests that the 
antioxidant is not able to provide any beneficial effects at any concentration.  
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5.1 - Introduction 
There will be a need for effective transportation methods for cell-based products 
if, in the future, allogeneic cell therapies are used routinely in the clinic to treat 
disease. As discussed previously, cryopreservation is currently the most common 
way to maintain cell viability during transit, but this is plagued with problems such 
as a significant loss of cell viability and function, toxic cyropreservants, special 
and expensive storage conditions, and an increased risk of infection due to an 
increased level of handling75. Intercytex® have developed a means to transport 
cells in a refrigerated state for short time periods79, but the ideal would be to 
develop a way to transport cells under ambient room temperature.  
 
It has been hypothesized that primary cells could survive at room temperature for 
prolonged periods within an enclosed vessel, if the following was provided:- 
- a modified-release, serum-free nutrient delivery system, delivering nutrients to 
the cells at a constant rate, 
- a toxin adsorbent, which would be able to adsorb any toxic metabolites 
released, 
- a surface for anchorage-dependent cells to attach to, 
- access to atmospheric gases. 
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A key assumption surrounding this hypothesis is that the transported cells would 
remain viable at room temperature. 
 
In order to test the hypothesis made above, studies were configured where the cell 
viability was assessed after primary human mesenchymal stem cells (hMSCs) 
were left at room temperature within a well-plate format for up to 7 days. Seven 
days would allow cell therapy products to be transported internationally, and 
potentially allow parts of the world that lack cell culture facilities to access these 
treatments.  
 
The aims of this experimental chapter were first to determine whether it was 
possible to culture hMSCs under room conditions if all other parameters were 
optimal, and secondly to focus on the identification of an absorbent or adsorbent 
material that would effectively remove metabolic toxins from the system without 
having any detrimental effects on the cells. Such a material would allow the liquid 
volume that the cells were transported in to be reduced (as, without such a 
material, a large volume would be required to dilute the toxins to a non-harmful 
level), allowing for the transportation vessel to be more compact. 
 
Throughout this chapter, the cells were incubated at room temperature within a 
medium free from xenogeneic serum. This was to ensure that, if a transportation 
device were to be developed, no xenogeneic substances could be delivered to the 
patient, which may potentially be harmful. 
 
5.2 – Materials and methods 
5.2.1 – The effect of media volume on hMSC culture under room conditions 
The cells were transferred to transwells as described in 2.2.2.1. The transwells 
were then moved to either wells or beakers (for when the media volume was 
greater than 10 ml) containing the following volumes of StemPro® media, pre-
warmed to 37 °C, in ml: 2, 5, 10, 20 and 50. After a day elapsed, the cells were 
analysed for viability using the alamar blue assay (2.2.4). 
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After 7 days of culture at room temperature, one transwell from the remaining 
viable volume groups were placed back into a tissue culture incubator, whist the 
remaining 2 transwells per group remained at room temperature. Viability analysis 
of all transwells continued using the alamar blue assay (2.2.4). 
 
This study was repeated using differing volumes of pre-warmed StemPro® media: 
2, 5, 8 and 10 ml. After 1, 4 and 7 days, the cells were analysed for viability with 
the use of the Mitotracker® Deep Red stain (2.2.5) followed by flow cytometric 
analysis (2.2.6).  
 
5.2.2 – The effect of metabolic toxins and prolonged detachment on cell viability 
After the hMSCs were processed as described in 2.2.2.1, the transwells were 
transferred to wells containing 5 ml of pre-warmed StemPro® media. The 
following toxins were added to the wells: 500 nl of a 35 % ammonia solution (1.81 
mM) or 9 mg lactic acid (20 mM). To assess prolonged cell detachment, the cells 
were plated onto non-tissue plastic well plates and incubated within a tissue 
culture incubator for 24 hours before culturing the cells at under room conditions. 
To determine the level of viability, the alamar blue assay was used (2.2.4), using 
centrifugation (250 g, 4 minutes) to ensure that solutions could be changed without 
losing viable detached cells. 
 
5.2.3 – The ammonia adsorptive properties of zeolite and activated carbon 
Ammonia solution (35 % v/v) was added in 5 µl increments to 10 ml of phosphate-
buffered saline (PBS) (control) or 10 ml of PBS containing 4 g of either pre-
prepared zeolite (2.2.7) or activated carbon. Due the mild acidic effects of the 
zeolite, this was compared to zeolite, in PBS, with the pH pre-adjusted to be the 
same as control (pH 7.4) using molar sodium hydroxide (this pre-adjustment was 
not necessary for the PBS containing activated carbon). After each ammonia 
addition, the pH was measured and recorded using a Mettler Toledo SevenMulti® 
pH meter. 
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5.2.4 - Nutrient adsorption from media containing either zeolite or activated 
carbon 
Pre-prepared zeolite (2.2.7) or activated carbon (4 g) was placed into 10 ml of 
complete StemPro® media. After each day at room temperature, the media was 
replaced with fresh media, and the extracted samples were analysed for both 
glucose (2.2.8) and total protein content (2.2.9). 
 
5.2.5 – The effect of zeolite on cell viability under room conditions 
After culturing the hMSCs onto wells in a 6 well plate (2.2.2.1), the ammonia was 
managed either through the addition of 4 g of pre-prepared zeolite (2.2.7), within a 
transwell (figure 5.1) or through the manual adjustment of the pH to 7.4, every 12 
hours, using 100 mM hydrochloric acid (HCl). All cell samples contained 5 ml of 
pre-warmed StemPro® and 5 ml PBS (as the volume needed to be more than 5 ml 
in order to submerge the zeolite within the solution). After 1, 2, 4 and 7 days of 
culture under room conditions, 3 transwells from each group were sacrificed, and 
the cells were analysed for viability using the CellTiter AQ One Solution Cell 
Proliferation Assay (2.2.3). 
 
5.2.6 – Ammonia release from hMSCs cultured under room conditions 
After the cells were cultured and analysed for viability as described in 5.2.5, the 
cell culture media was retained. This media (50 µl) was mixed with 50 µl of 
working Biovision® ammonia assay reagent (appendix 2.5) and incubated at 37 ºC 
for 60 minutes. Colorimetric analysis was carried out at 570 nm using a Bio-Tek 
KC4 plate reader. Blank values were subtracted from sample readings, and, using 
a standard curve (appendix 5.7), the concentration of ammonia was determined. 
 
5.3 – Results 
5.3.1 – The effect on media volume on hMSC culture under room conditions 
Figure 5.2 documents the number of hMSCs present during 11 days of culturing 
with varying volumes of StemPro® media. Cells within all volumes showed the 
cell number almost doubled after 1 day of culture. Cells cultured within a media 
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Figure 5.1. Schematic of well plate configuration to assess the 
effectiveness of the zeolite (III) in supporting cell viability at room 
conditions. The hMSCs (IV) were seeded onto a well of a 6-well plate (V), 
and the zeolite was suspended above the cells using the a Corning 
Transwell® (I). The cells were cultured in a solution (II) containing 5 ml 
StemPro® media, with 5 ml PBS to ensure that the entirety of the zeolite was 
in solution. 
II 
I 
III 
IV 
V 
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Figure 5.2. Viability of hMSCs following specific periods under ambient 
room conditions within the following volumes of StemPro
®
 media (ml): 2 
(), 5 (), 10 (), 20 (×) and 50 (+). Determined using the alamar blue 
assay. Results represent mean viability ± SEM. The study was carried out in 
triplicate up to day 7, after which point the study was performed in duplicate. 
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volume of 10 ml and above saw a gradual decrease in viable cells from days 1 to 9, 
followed by a dramatic decrease in viability, leading to a small number of cells 
being viable at day 11, regardless of the volume of media they were in of 10 ml 
and above. Cells cultured in volumes of 5 ml and below showed a very different 
viability profile; a dramatic fall in viability was seen after day 1 so that few cells 
were viable at day 4. 
 
The subset of cells that were placed back within favourable conditions within a 
tissue culture incubator after 7 days under room conditions were found to 
proliferate, after a lag phase of 2 days, at a rate similar to that seen at the first day 
of culture within room conditions (figure 5.3). This proliferation was found to 
cease after 5 days within the tissue culture incubator; this is thought to be due to a 
restriction in expansion space. 
 
When repeating this study using a mitotracker® stain, followed by flow cytometric 
analysis, the results were found to be vastly different to those seen in figure 5.2; no 
significant increase in cell number was seen after the first day of culture under 
room conditions in any of the volumes of media, and the majority of cells were 
found to be non-viable after 7 days of culture (figure 5.4). Only the volume of 10 
ml was found to show no significant decrease in viability after 4 days of culture at 
room temperature (< 0.05). 
 
5.3.2 – The effect of metabolic toxins and prolonged detachment on cell viability 
The number of viable hMSCs decreased significantly when cultured on to non-
tissue culture plastic and when ammonia was introduced into the culture, 
compared to control ( < 0.01) (figure 5.5). However, the cells tolerated the 
introduction of lactic acid and this led to a significantly increased level of viability 
after 5 days compared to control ( < 0.01). 
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Figure 5.3. Proliferative count of hMSCs under favourable conditions 
following 7 days under room conditions within the following volumes of 
StemPro
®
 media (ml): 10 (), 20 (×) and 50 (+). Proliferation rates were 
determined using the alamar blue assay. The results did not have any replicates 
(hence no error bars) Sample data were plotted on an exponential axis. 
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Figure 5.4. Viability of hMSCs following specific periods under ambient 
room conditions within the following volumes of StemPro
®
 media (ml): 2 
( ), 5 ( ), 8 ( ) and 10 ( ). Samples were compared against control ( ).  
At specific timepoints, samples were incubated mitotracker® deep red dye 
according to the manufacturers’ instructions before being analysed using a 
Beckman Coulter Cytomics FC500 flow cytometer at 60 µl/min. Samples 
were analysed using WinMDI. Results represent mean viable cell number ± 
SEM. Asterisks represent the level of significance compared to control sample 
(< 0.01). 
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Figure 5.5. Viability of hMSCs following specific periods under ambient 
room conditions within 5 ml of StemPro
®
 media introduced to a single dose 
of toxin, compared against no toxin introduction ().The following toxins 
were added: 500 nl of a 35 % ammonia solution (1.81 mM) ( ) and 9 mg lactic 
acid (20 mM) (t). Cells were also seeded onto non-tissue culture plastic (). 
Viability was determined using the alamar blue assay. Results represent mean 
viability ± SEM. 
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5.3.3 – The ammonia adsorptive properties of zeolite and activated carbon 
Figure 5.6 shows the increase of pH when ammonia was added to PBS containing 
zeolite or activated carbon. Both zeolite and activated carbon both significantly 
reduced the pH increase with each addition of ammonia ( < 0.01). The pH-
reducing effect of the zeolite was not hindered by the addition of molar sodium 
hydroxide (NaOH), used to increase the slightly acidic solution to pH 7.4. 
 
5.3.4 - Nutrient adsorption from media containing either zeolite or activated 
carbon 
Activated carbon significantly reduced the level of total protein from complete 
StemPro® over 2 days, compared to complete media ( < 0.05), but did not have 
any significant affects on the glucose concentration. Zeolite had no significant 
effect on glucose or total protein levels (figure 5.7). It was also observed that, 
during the first 3 days, the yellow colour of the media disappeared from the 
activated carbon samples, and turned colourless (data not shown). 
 
5.3.5 – The effect of zeolite on cell viability under room conditions 
Figure 5.8 compares the viability of samples containing zeolite to samples that 
were manually pH controlled, compared to control. All samples were seen to 
increase in viability after 1 day of culture at room temperature. After days 4 and 7, 
both the pH controlled group and the zeolite-containing group showed a 
significantly higher level of viability compared to control. No significant 
differences were observed between the zeolite group and the pH-controlled group. 
 
5.3.6 – Ammonia release from hMSCs cultured under room conditions 
Figure 5.9 compares the level of ammonia present in the media when the hMSCs 
were cultured under room conditions for samples containing zeolite, or that were  
manually pH controlled, compared to control. Within all samples, ammonia was 
seen to increase drastically during the first day of culture, then decrease slowly 
over the next six days. A significantly lower concentration of ammonia was 
present in the zeolite-containing group compared to the other groups, though the 
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Figure 5.6. pH values of 10 ml ammonia solutions in PBS, containing either 
(i) 2 g  pre-prepared zeolite granules (), or (ii) 2 g pre-prepared zeolite, pH 
pre-adjusted to 7.4 using 1 M NaOH (), or (iii) 2 g activated carbon () 
compared to solution containing no adsorbant ( ). pH was measured using a 
calibrated Mettler Toledo SevenMulti® pH meter. Results represent mean pH ± 
SEM 
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Figure 5.7. Glucose () and total protein (t) concentration within 10 
ml complete StemPro media following adsorption from 2 g of either zeolite 
granules (white) or activated carbon  (black). After each day, media was 
extracted from the adsorbent, either through simple pipetting (zeolite) or through 
vacuum filtration (carbon). The extracted media was replaced with fresh media. 
The glucose concentration within the extracted samples was determined using 
the glucose oxidase assay. The total protein concentration was determined using 
the Coomassie Plus assay. Results represent mean concentration ± SEM 
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Figure 5.8. Viability of hMSCs following specific periods under ambient 
room conditions within 5 ml of StemPro
®
 media ( ). Ammonia 
accumulation was managed either through the introduction of 4 g zeolite 
() or by the adjustment of pH every 12 hours  to 7.4 using 100 mM HCl 
(). Determined using the CellTiter AQ Proliferation assay. Results represent 
mean viability ± SEM. Asterisks represent the level of significance compared to 
control sample (< 0.01). 
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Figure 5.9. Ammonia concentration within 5 ml StemPro
®
 media 
samples cultured with hMSCs under ambient room conditions, either in 
the presence of 4 g zeolite (), or with the 12 hourly adjustment of pH 
to 7.4 using 100 mM HCl (), compared to control ( ). Determined using 
a Biovision® ammonia detection assay. Results represent mean viability ± 
SEM. 
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 level of the ammonia within the zeolite-containing group was still significantly 
higher than the ammonia level of fresh media ( < 0.01). 
 
5.4 – Discussion 
Here, the feasibility of a transportation system that maintains viable cells under 
ambient room conditions was assessed. The development of such a system would 
significantly reduce the transportation costs compared to cryopreserved delivery. 
This system would also minimise the level of processing on the cell suspension 
that would be required before delivery to the patient, thus leading to a lower risk of 
contamination and a reduction of the processing facilities required at the clinic 
where the patient would be treated. 
 
The development of such a transportation system relied upon the assumption that 
primary cells would remain viable at room temperature if all other variables were 
optimal. Developing a study where the cells were incubated within a high volume 
of media was used not only to provide a plentiful supply of nutrients, but also to 
thoroughly dilute any metabolic toxins released from the cells. Fortunately, with 
regard to hMSCs, our initial findings showed that cell viability did not decrease 
significantly over a 9 day period ( < 0.05). Similar results were reported in Lane 
 ; they showed no decrease in viability when the cells were stored at room 
temperature, though they only assessed viability over a shorter 24 hour period81. 
However, after 1 day, the cells did not proliferate either, but entered a state of 
proliferative arrest. This arrest phase appeared to be reversible, as when the cells 
were placed at 37 °C, they were able to proliferate at rate similar to cells not 
exposed to a temperature change, after a lag period of 2 days. There are other 
reports of a reversible proliferative arrest state; Macip and co-workers reported 
such a reversible state in cancer cells when exposed to a certain concentration of 
reactive oxygen species119, and Stolzing reported a similar observation with 
MSCs120. 
 
Chapter 5   The identification of a toxin adsorbent 
   
  89 
A note-worthy observation is that, regardless of the level of nutrients provided, all 
of the cells became non-viable soon after 9 days at room temperature. Nine days 
may be the window of reversible arrrest with this cell type, after which cell death 
through apoptosis ensues. 
 
If this reversible arrest state does not damage the cells, this state would be 
beneficial for the transportation device; if the cells are not proliferating, the 
nutrient demands, and the level of the metabolic toxin release would be lower. The 
cell number within the vessel after a 7 day period could also be easier to accurately 
predict. However, the lag phase when the cells are returned to 37 °C (when 
delivered to the patient) of 2 days before proliferation occurs may be too long, as 
the cells may need to engraft within the delivered site quickly to ensure they are 
not cleared. This may be easily dealt with by recommending a clinic to incubate 
the transportation vessel at 37 ºC for 2 days before administering the suspension, 
though this would require the clinic to have facilities to do so. 
 
Between chapters 3 and 4, a close viability correlation was seen between cells 
analysed using mitochondrial staining and flow cytometry compared to cells 
analysed using a colorimetric mitochondrial assay. However, when comparing the 
viable cell number in figure 5.2 (determined using alamar blue) against figure 5.4 
(determined using flow cytometry), differing results are observed. This difference 
increases the importance for further analysis of this arrest state, as it may be 
possible that, between day 4 and 7, where the large difference in viability is seen, 
there is early damage to the mitochondria that has not led to a change in chemical 
reduction within the media (detected by the alamar blue).   
 
With regard to the study incorporating metabolic toxins within the culture, the 
main aim was to assess whether the cells were more sensitive to the toxins when at 
room temperature rather than at 37 ºC. The toxins that would be analysed, and 
their concentration, were determined from a review by Schneider , who stated 
that lactic acid and ammonia concentrations of 20 and 2 mM respectively could 
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inhibit cell growth121. The hMSCs were indeed more sensitive to ammonia; this 
concentration caused cell death within 2 days, although it is worth noting that the 
ammonia added to the culture would be in addition to any ammonia the cells 
released, this further increasing the concentration. A similar observation has been 
seen previously by Macip and co-workers, who found that cancer cells within the 
reversible arrest state are more sensitive to chemotherapeutic agents119. The lactic 
acid caused an increase in viability, and this may be due to the acid partially 
neutralising the ammonia released, keeping the pH closer to 7.4. This may also be 
due to the lactic acid causing an activation of metabolism as the cells attempt to 
repair themselves or activate an apoptotic cascade, as detailed in Boyle and 
Hickman122. 
 
The hMSCs, not surprisingly, reacted unfavorably when they were not attached to 
a surface. A decrease in viability and an increase in apoptosis within anchorage-
dependent cells followed prolonged periods of detachment have been reported 
previously92. This finding suggests that a transportation system incorporating the 
poly(lactic--glycolic) acid microparticles developed in Chapter 3, as a scaffold 
that the cells can attach to, may be of benefit. 
 
As ammonia is deemed a more toxic metabolite under aerobic conditions 
compared to lactic acid121, and the results above showed that the cells were 
sensitive to ammonia, it was decided that an ammonia adsorbent would be 
identified and utilised. The two toxin adsorbents assessed were activated carbon 
and zeolite. Activated carbon, derived from charcoal, is an effective and cheap 
adsorbent, due to its extremely porous structure (figure 5.10). Activated carbon is 
found to be non-toxic and is currently used to adsorb poisons ingested by overdose 
patients123. 
 
Zeolites are natural, abundant, crystalline, hydrated aluminosilicates, that consist 
of pores containing alkali and alkaline earth cations, such as as Na+, K+, Ca2+ and 
Mg2+. These cations are often loosely held, allowing the easy exchange of other 
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cations, such as ammonium (NH4
+), which is contained with a higher affinity. 
Zeolites are currently used to filter ammonia from industrial and agricultural 
waste. Zeolites are classed as biocompatible and are used to filter blood as part of 
kidney dialysis equipment124. 
 
In a simple pH experiment, activated carbon and zeolite were found to adsorb 
ammonia equally as effectively. For this reason, the toxin adsorbent that would be 
used was chosen based on its ability adsorb ammonia  and not adsorb 
useful nutrient components. Even though glucose and total protein, which were 
both analysed in this study, do not represent all that a cell requires from cell 
culture media, the concentration of these two nutrients were analysed for two 
reasons; (i) both nutrients are vitally important to the cells and excessive 
adsorption of either component would have detrimental effects on the cells, and 
(ii) both components are very different from one another, mainly in terms of 
molecular weight and size. Therefore, analysing the adsorption of both nutrients 
could provide information with regards to whether preferential adsorption occurs 
for one molecule over another.  
 
The activated carbon was found to adsorb significant amounts of protein from 
complete StemPro® media compared to the same weight of zeolite. These results 
link with work published by Petit , who found that activated carbon is not as 
effective at adsorbing ammonia than other substances (the opposite to the 
adsorption profile of the zeolite) and were developing means to increase its affinity 
towards ammonia125. These experimental results, together with the current 
literature, do suggest that zeolite would be more specific to ammonia than 
activated carbon if not totally specific, and for these reasons, the zeolite was 
chosen as the toxin adsorbent to use in the cellular studies. 
 
Zeolite was seen to increase the viability of the cells to a similar extent as the 
manual pH adjustment. It was expected that zeolite would provide a higher level of 
viability over the pH-adjusted group because the zeolite would prevent the 
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ammonia from having negative molecular effects on the cells, as well as maintain 
the pH at 7.4. At a molecular level, ammonia is thought to be able to increase 
additional ammonia release through the activation of glutaminase (as well as 
reduce glutamine levels) and cause futile energy dissipation through the 
interference of a glutamate dehydrogenase pathway. However, the removal of 
these negative molecular effects may be countered by the effect of potential 
nutrient adsorption. 
 
The zeolite was also found to significantly reduce the level of ammonia present in 
the culture compared to the pH-controlled group or the control ( < 0.05), though 
was not able to totally remove the ammonia. The plateau in ammonia, seen in all 
groups, was probably due to the low level of metabolism occurring within the cell 
samples during their arrest phase. However, this could also be due to the ammonia 
evaporating off from the samples as it was being produced by the cells. 
Interestingly, the results shown in figure 5.8 and 5.9 suggest that an increase in 
ammonia of as little as 120 µM, can cause a significant decrease in viability after 4 
days, displaying the high level of sensitivity the cells have towards ammonia at 
room temperature. 
 
5.5 – Conclusion 
In this chapter, the overall aim was to develop a means of transporting viable 
primary cells under room conditions. Displayed here is initial evidence that 
hMSCs are able to survive under these room conditions for between 4-9 days. 
Even though the cells appear to enter a proliferative arrest phase under these 
conditions, the arrest was found to be reversible when the cells were placed back 
into favourable conditions. 
 
Under room conditions, hMSCs were found to be sensitive towards the presence of 
low levels of ammonia, so it was decided that an adsorbent that could remove 
ammonia from the system would be identified. Even though activated carbon and 
zeolite showed similar ability to adsorb ammonia, the literature, together with the 
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findings here, suggested that carbon would adsorb a substantial amount of 
nutrients compared to zeolite, so zeolite was chosen for further analysis. 
 
The initial results suggest that the presence of zeolite leads to a substantial 
improvement in hMSC viability, and that this improvement in viability is due to 
the zeolite removing ammonia from the system. 
 
5.6 – Future Work 
The methods used act as simple surrogate markers, providing an insight into the 
plausibility of cells remaining functional after transportation under room 
conditions and whether a toxin adsorbent could improve the likelihood of the cells 
remaining viable. Further studies are required in order to fully determine whether 
these initial results are correct. 
 
Further analysis of the reversible proliferative arrest phase seen whilst the cells are 
under room conditions is required, such arrest-associated β-galactosidase staining 
and cell cycle analysis, to determine the mitotic checkpoint the cells arrest at, in 
order to ensure that cells are not damaged irreversibly after incubation under room 
conditions. In addition, a more robust assessment of cell morphology and function 
is required in order to fully determine whether the incubation under room 
conditions has had a detrimental impact on the cells. Analysis of cell attachment 
and spreading, and the level of apoptosis that occurs, using methods described in 
Chapter 3, would be beneficial to this study.  
 
Ideally, flow cytometric analysis would have been used throughout this chapter, 
not only for the reasons stated in 4.1, but also because of the large discrepancy in 
results obtained from flow cytometric and colorimetric analyses, as described 
above. However, the particulate zeolite matter could not be effectively removed 
from the cell suspensions, which could have potentially caused false positives 
when analysed through flow cytometry. For this reason, when the zeolite was 
present, the CellTiter AQ One Solution assay was used instead. 
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Assessing the ability of these adsorbents to adsorb protein and glucose alone is by 
no means a fair representation of all cellular nutrients, and the zeolite may adsorb 
other important nutrients that have not been tested; reports have found that 
clinoptilolite, a form of zeolite, inhibited tumour cell proliferation, and it was 
predicted that this inhibition was through an adsorption of calcium from the 
media126. Ideally, a high performance liquid chromatography (HPLC) method 
would have been applied to the adsorbed samples in order to fully identify what 
nutrients had been removed. The use of HPLC would also be able to assess 
whether any substances are leaching out from the zeolite that may be harmful to 
the patient. 
 
As the zeolite used was a natural mixture of many different aluminosilicates, using 
a specific zeolite with a high affinity for ammonia, such as clinoptilolite, may have 
reduced the ammonia levels further, as suggested by the literature126,127,128. This 
specific zeolite, however, was found to be very difficult to source. 
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6.1 - Introduction 
Chapter 5 identified zeolite as an effective adsorbent for the metabolic toxin 
ammonia that was able to significantly improve human mesenchymal stem cell 
(hMSC) viability after 7 days under room conditions. Although these findings are 
encouraging, the volume of cell culture media used was high; to culture 100,000 
cells for 7 days, 5 ml of serum free media was used. Typically, for cell therapy 
studies, the number of cells delivered could be as high as 1010 (Martin-Rendon 
, 33 requiring respectively up to 500 litres of media. Even if a cell transportation 
vessel could be designed to ensure this high volume of liquid was not delivered to 
the patient when the vessel arrived at the clinic, this volume would make the 
vessel very cumbersome to transport and would significantly increase the costs of 
the media and the materials required. 
 
Here, a method of forming a concentrated nutrient supply for hMSCs under 
ambient conditions was developed, which then led to the development of a 
controlled nutrient release system. The controlled nutrient release system was 
developed for two hypothetical reasons:- 
- Concentrating a nutrient supply could have effects on osmolarity, as well as 
direct cellular effects, that could be detrimental rather than beneficial to the 
cells. A controlled release system would theoretically ensure that the nutrients 
were released at a rate similar to consumption and therefore, the concentration 
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of nutrients within the liquid phase would remain at non-toxic levels 
throughout transportation. 
- Despite the initial results suggesting that the adsorbent material does not 
adsorb glucose or proteins from cell culture media (Chapter 5), the zeolite 
may adsorb other nutrients, as well as ammonia; reports have shown that 
calcium level could be depleted by the presence of zeolite126. Within a system 
containing concentrated nutrients, it is possible for the zeolite to adsorb 
important nutrients soon after its introduction, causing both an immediate 
reduction of nutrients for the cells and a reduced adsorptive capacity of the 
zeolite. Within a system containing a nutrient release gel, a diffusion gradient 
could be achieved, where nutrients pass the cells before being potentially 
adsorbed by the zeolite. 
 
An alginate gel was developed to form the controlled release system. Due to 
alginate’s ability to polymerise at room temperature through the use of multivalent 
cations (such as Ca2+ and Ba2+) interacting with carboxylic acid groups on the 
polysaccharide backbone, forming gels in this fashion could ensure that any 
required protein nutrients would not denature. Alginate also has the advantages of 
being biocompatible and cheap to source129. 
 
6.2 – Materials and Methods 
6.2.1 – The effect of specific nutrients on cell viability 
After the hMSCs were processed as described in 2.2.2.1 into wells of a 6 well 
plate, the following nutrients were added on a daily basis: 2 mg glucose (2.2 mM), 
2 mg fructose (2.2 mM), 50 µl glutamine (200 mM), 50 µl glutamax® (200 mM), 
100 µl StemPro® supplement or 10 mM HEPES buffer. To determine the level of 
viability, the alamar blue assay was used (2.2.4). 
 
6.2.2 – Comparison of concentrated StemPro® against standard media 
Concentrated StemPro® media was created as described in appendix 1.4. The 
concentrated media was reconstituted with tissue culture water in order to make 
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the media standard strength once more. After the hMSCs were transferred to a 6 
well plate at the concentration of 104 cells/well, as described in 2.2.2.1, the cells 
were cultured in a tissue culture incubator for up to 7 days. The number of viable 
cells was determined daily using the alamar blue assay (2.2.4). 
 
6.2.3 – Alginate Gel Fabrication 
A stock solution of 5 % (w/v) alginate was prepared by dissolving pre-autoclaved 
(121 °C at 1 bar for 1 hour), high viscosity alginate in Dulbecco’s modified Eagle 
medium (DMEM) or concentrated StemPro®. After initial mixing, the solution was 
left on a heated magnetic stirrer for up to three hours at 37 °C to completely 
dissolve the alginate. 
 
In order to polymerise the gel, a hole was made on the underside of a 34 mm 
diameter petri dish using a heated scalpel blade and inverted onto nylon filter 
paper. The alignate gel was weighed onto the filter paper and smoothed to the 
edges. The alginate, together with filter paper and petri dish, were placed into a 
100 mm diameter petri dish containing 1 % (w/v) barium chloride polymerisation 
buffer. This was moved to a cell culture incubator and incubated for 16 hours. 
 
The polymerising method was optimised after it was found that the gel failed to 
become stiff enough. The following parameters were altered: (i) the concentration 
of barium within the polymeristation buffer increased to 2 %, (ii) a layer of 
polymerisation buffer was slowly pipetted on top of the gel within the smaller petri 
dish, (iii) 2 hours after incubation, the gel was slowly peeled away from the filter 
paper, and placed upside-down into a petri dish containing fresh polyerisation 
buffer. The gel was adequately stiffened after a further 2 hours (figure 6.1). 
 
The lowest weight of alginate that could be practically weighed and spread evenly 
into the petri dish was 2 g. Therefore, when gels of 500 mg and 1 g were required, 
the gel was cut into quarters or halves after it was stiffened. The sections were then  
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Figure 6.1 – Schematic showing the optimized polymerisation of alginate 
gels. A hole was made on the underside of a 34 mm diameter petri dish using a 
heated scalpel blade (I) and inverted onto nylon filter paper (IV). Alginate gel 
(5 % w/v) (III) was weighed onto the filter paper and smoothed to the edges. 
The alginate, together with the filter paper and petri dish, were placed onto a 
100 mm diameter petri dish (V) containing 2 % (w/v) barium chloride 
polymerisation buffer (II). Additional polymerisation buffer was slowly added 
on top of the alginate gel. This was moved to a cell culture incubator. After 2 
hours, the gel was slowly peeled away from the filter paper, and placed upside-
down into a new petri dish containing fresh polymerisation buffer. The gel was 
adequately stiffened after a further 2 hours. If necessary, the gels were cut into 
halves or quarters and placed back into fresh polymerisation buffer for a further 
hour in order to stiffen the sections exposed by the sectioning. 
Side 
View 
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View 
I 
II III 
IV 
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placed back into fresh polymerisation buffer for 1 hour in order to stiffen the areas 
exposed by the sectioning. 
 
6.2.4 – Release kinetics from alginate gels 
The gels were placed into 5 ml of phosphate buffered saline (PBS). After each day 
at room temperature the PBS was replaced with fresh PBS and the extracted 
samples were analysed for both glucose (2.2.8) and total protein content (2.2.9). 
 
The reasons for analysing glucose and total protein release are similar to those 
discussed in 5.2.4; both glucose and protein are important nutrients for cell 
viability, and the molecules differ so greatly in size and molecular weight that 
analysis of both release profiles could provide information regarding whether 
preferential release for one over the other occurs. 
 
6.2.5 – The effect of the developed nutrient release system on cell viability 
After the hMSCs were transferred to the transwells as described in 2.2.2.1, the 
cells were arranged in a disposable beaker as shown in figure 6.2. The control 
consisted of the configuration without the gel or zeolite, but instead with 500 µl of 
5 × concentrated StemPro® media in 5 ml of PBS within the transwell. All the 
other samples contained 4 g of pre-prepared zeolite (2.2.7). The transwells were 
placed on top of the zeolite, which was submerged in 5 ml of PBS. A pre-fed 
group was arranged, which was similar to the control except that it did contain 
zeolite. A regularly fed group was configured in a similar manner to the pre-fed 
group except with the addition of 125 µl concentrated media to the transwell at day 
0, 2, 4 and 6, instead of 500 µl at day 0. Finally, two cell groups containing a 500 
mg nutrient gel were configured, one group with the gel placed with the zeolite, 
and the other where the gel was placed floating above the cells within the 
transwell. 
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Figure 6.2. Configurations used to assess the effectiveness of the zeolite 
(III) and the alginate nutrient gel (VI) in supporting cell viability at 
room conditions. The study needed to be set up within a disposable 100 ml 
beaker (V), rather than a well plate, in order to accommodate the 4 g zeolite 
and the 500 mg gel. After the hMSCs (IV) were seeded onto the transwells 
(I) two set ups were used, one where the gel was placed with the zeolite 
within the beaker (A), and the other where the gel floated above the cells 
within the transwell (B). PBS (5 ml) was placed in the beaker, with an 
additional 5 ml within the transwell (II) so that the zeolite and the cells were 
in solution. 
A 
I 
II 
III 
IV 
V 
VI 
I 
II 
III 
IV 
V 
VI 
B 
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After 1, 2, 4 and 7 days of culture under room conditions, three transwells from 
each group were sacrificed, and the cells were analysed for viability using the 
CellTiter AQ One Solution Cell Proliferation Assay (2.2.3). 
 
6.3 – Results 
6.3.1 – The effect of specific nutrients on cell viability 
In general, no one specific supplement provided a clear improvement in viability 
compared to control throughout the study (although daily supplementation with 
glutamax® did provide a significant improvement after days 3 to 5 of culture under 
room conditions) ( < 0.05) (figure 6.3). HEPES buffer caused a significant 
decrease in viability compared to control after one day of culture ( < 0.01). The 
majority of cells were found to be non-viable after 5 days of culture at room 
temperature. 
 
6.3.2 – Comparison of concentrated StemPro® against standard media 
After extensive shaking, the freeze-dried basal media had not fully dissolved 
within the liquid and, therefore, some supplements were lost when the media was 
filter-sterilised (data not shown). However, despite this loss of supplements, the 
concentrated media, following reconstitution, was found to be as effective as 
standard media in aiding the hMSC proliferation under optimal conditions within a 
tissue culture incubator (figure 6.4). 
 
6.3.3 – Release kinetics from alginate gels 
Using the method developed initially to polymerise the alginate gel, all of the 
glucose was found to be released into the PBS within 3 days, together with the 
majority of the total protein (figure 6.5). The optimized method provided a more 
linear release profile for both the glucose and the protein over a 7 day period, 
though a clear burst phase was still observed with relation to the glucose. 
 
When the optimised polymerisation technique was applied to the concentrated 
StemPro® media, a reasonably constant release of protein was seen from day 4 to 7  
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Figure 6.3. Viability of hMSCs following specific periods under ambient 
room conditions within 5 ml of StemPro
®
 media supplemented daily 
with various nutrients, compared against no supplementation (). The 
following nutrients were added to the media on a daily basis: 2 mg glucose 
(2.2 mM) (), 2 mg fructose (2.2 mM) (), 50 µl glutamine (200mM) (+), 
50 µl glutamax® (200mM) (×), 100 µl StemPro® supplement (-) and 10mM 
HEPES buffer (). Viability was determined using the alamar blue assay. 
Results represent mean viability ± SEM. 
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Figure 6.4. Proliferative count of hMSCs under favourable 
conditions, comparing complete StemPro
®
 media ( ) with 5 × 
concentrated media reconstituted to normal strength using tissue 
culture water (). Proliferation rates were determined using the alamar 
blue assay. Results represent mean viability ± SEM. Sample data were 
plotted on an exponential axis. 
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Figure 6.5. Glucose () and total protein (t) concentration within 
5 ml PBS following release from alginate gels (5 g) containing complete 
Dulbecco’s modified Eagle’s medium, fabricated using an initial 
method (black) or through an optimised method (white). After each day, 
the PBS was removed and replaced with fresh phosphate-buffered saline. 
The glucose concentration within the extracted samples was determined 
using the glucose oxidase assay. The total protein concentration was 
determined using the coomassie plus assay. Results represent mean 
concentration ± SEM 
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(figure 6.6). However, the concentration of glucose was found to be lower within 
the gel, leading to very low levels of glucose released at day 6 and 7.   
 
6.3.4 – The effect of the developed nutrient release system on cell viability 
Figure 6.7 documents the number of viable hMSCs after being incorporated within 
various nutrient release configurations. The viability profile was found to be 
similar to what was observed in figure 5.8; an increase in viability was seen at day 
1, followed by a gradual decrease in viability. After 7 days under room conditions, 
the presence of the zeolite was again shown to significantly improve viability 
compared to no zeolite being present ( < 0.01). Providing the nutrients gradually 
every other day provided no significant improvement in viability compared to 
providing the nutrient at day 0 ( < 0.05). Neither of the gel configurations 
provided a significant improvement over pre-fed or regular feeding groups, 
instead, the gel incorporated with the zeolite was found to significantly decrease 
the level of viability compared to all other groups after 4 days.  
 
6.4 – Discussion 
Providing the cells with a concentrated form of all the nutrients they require would 
allow for the development of a more compact transportation vessel for the cells, 
which would, in turn, reduce the costs both of materials and transporting bulky 
items. 
 
Figure 6.3 clearly shows that the cells requirements are complex and various; one 
nutrient alone does not provide any substantial benefit, instead, the cells require 
numerous nutrients at the correct levels. The cell’s requirement for complex 
culture media has been documented previously92. However, this study did suggest 
the use of some supplements over others within the media; cells supplements with 
glutamax® supplement showed a significant improvement in viability at days 3 to 
5 compared to both control and cells supplemented with glutamine. Glutamax® 
contains a stable dipeptide form of glutamine, L-alanyl-L-glutamine, that is less 
prone to degradation (producing ammonia) than single glutamine amino acids130.   
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Figure 6.6. Glucose () and total protein () concentration within 5 ml 
PBS following release from alginate gels (1 g) containing 5 × 
concentrated StemPro
®
 media, fabricated using the optimised method. 
After each day, the phosphate-buffered saline was removed and replaced 
with fresh PBS. The glucose concentration within the extracted samples was 
determined using the glucose oxidase assay. The total protein concentration 
was determined using the Coomassie Plus assay. Results represent mean 
concentration ± SEM 
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Figure 6.7. Viability of hMSCs following specific periods under ambient 
room conditions within PBS containing zeolite. Nutrients were provided 
to the cells either through pre-feeding (), feeding at regular intervals 
(), or through the use of a controlled nutrient release system (¡) 
and compared to pre-fed controlled samples containing no zeolite ( ). 
The pre-fed groups contained 500 µl of 5 × concentrated StemPro® media 
(equivalent to 2.5 ml standard strength media) within 5ml of phosphate-
buffered saline (PBS) within the transwell, and the transwells were placed in 
an additional 5 ml PBS, either containing or not containing 4 g zeolite, 
within a 100 ml disposable beaker. The regularly fed group received 125 µl 
of concentrated media at days 0, 2, 4 and 6. Alginate nutrient gels (500 mg) 
were fabricated as described in 6.2.3, and added to the transwell set up as 
depicted in figure 6.2; the gel was placed either with the zeolte with the 
beaker () or placed floating above the cells within the transwell (¡). 
Viability was determined using the CellTiter AQ Proliferation assay. 
Results represent mean viability ± SEM. 
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Using the glutamax® supplement is thought to reduce the level of ammonia in the 
culture, thus improving viability, and, for this reason, glutamax supplement was 
used in further experiments. 
 
It was not surprising that the level of viability would require the correct 
concentration of various nutrients, as, even under favourable conditions within a 
tissue culture incubator, the primary hMSCs were found to only proliferate in 2 
culture medias specific to hMSCs, one of which being the StemPro® media. Both 
medias also have a secret recipe that the manufacturers do not divulge, so a 
concentrated form could not be created from its individual components. Because 
the cells prefer StemPro® media to DMEM media, means of concentrating the 
effective media was developed, rather than reconstituting basal DMEM media 
powder, which is commercially available, with a smaller volume of water than 
recommended. Figure 6.4 showed that the freeze-drying method was an effective 
means of concentrating the media, with no obvious damage or loss of vital 
nutrients. 
 
The glucose and protein release profiles were not ideal; instead of providing a 
constant level of protein and glucose, a gradual decrease in the release of both was 
seen over a 7 day period. However, a burst release phase of nutrients may actually 
be beneficial in this circumstance; we have seen previously that cell proliferation 
only occurs during the first day under room conditions, suggesting that the 
majority of the cellular nutrient consumption would occur on that day. 
 
A lower level of glucose was released from the gels formed with concentrated 
media compared with gels formed with standard media throughout the 7 days 
release period. This may be because there is a lower concentration of glucose in 
the StemPro® media than standard DMEM. This may also be due to more glucose 
leaching out of the gel during the prolonged period within the polymerisation 
buffer (as the gel was placed back into polymerisation buffer after being cut into 
quarters in order to stiffen the exposed edges). 
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When applying the concentrated media to the cellular configuration, there was no 
significant benefit of providing the nutrients every other day to providing the 
nutrients at day 0. When taking into account the cellular trend of proliferation only 
on the first day, one would have expected the cells that were fed every other day to 
have a lower level of viability compared to the pre-fed group, as the regularly fed 
group would have only had a quarter of nutrients required to proliferate on day 1. 
This raises questions regarding the level of nutrients the cells actually require. 
 
Within the cellular experiment, half the level of nutrients (equivalent to 2.5 ml 
standard strength media) was applied to the system compared to the experiments 
carried out with the zeolite alone in Chapter 5. This was done deliberately to 
assess whether the level of nutrients that were required decreased with the 
presence of a toxin adsorbent. What is interesting is the similarity in the viability 
profile between that seen in figure 6.7 and figure 5.8; at day 7, a similar level of 
viable cell number is seen, and the rate of viable cell decrease is slightly greater in 
figure 5.8 than in figure 6.7. This similar level of viability may be because the 
nutrients were loaded into the transwell in figure 6.7, so the only way means of the 
zeolite accessing the nutrients was through the narrow pores (400 nm in diameter) 
of the transwell, which may have been preventing their passage. 
 
Also, the cellular configurations within this chapter contained 10 ml of PBS, rather 
than the 5 ml of PBS used in the previous chapter, allowing for a greater volume 
of liquid to buffer any changes in pH and to dilute any toxins released. 
Unfortunately, it is difficult to incorporate both the nutrient gel and the toxin 
adsorbent in solution and keep the volume of liquid to a minimum. 
 
The use of the nutrient gel did not significant improve viability compared to the 
pre-fed group and, instead, with regard to the gel placed with the zeolite, a 
significant decrease in viability occurred. This observation may have occurred for 
one of the following reasons; (i) the zeolite was adsorbing a nutrient vital to the 
cells from the gel before the it could reach the cells, (ii) the gel floating above the 
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cells led to a diffusion gradient through the cells, producing a steady flow of 
nutrients across the cells, or (iii) the transwell surface was preventing the passage 
of the nutrients to the cells. An effective way to test the third suggestion would be 
to form incisions on the transwell to ensure nutrients could flow through. 
 
The cells cultured with the nutrient gel placed in the transwell were found to be 
slightly less viable than the pre-fed or the regularly fed cells. This may have been 
due to the lower level of glucose in the gel, or because, when the beakers were 
moved, the gel would move and sometimes touch the cells. This viability profile 
may have also been because the breakdown products of the alginate released were 
harmful to the cells; this reason could have been tested by producing a group that 
contained an alginate gel containing only PBS. 
 
6.5 – Conclusions 
No one particular nutrient was found to significantly improve hMSC viability 
under room conditions apart from glutamax® supplement, which was added 
instead of glutamine to the media used in all subsequent experiments. 
 
It was not possible to produce a gel that produced a steady release of glucose and 
total protein, though it was envisioned that a burst release of nutrients may have 
been of benefit to the cells whilst they were proliferating during their first day in 
culture at room temperature. 
 
A method of creating a 5 × concentrated StemPro® media was developed, and this 
media was found to be as effective as standard strength media under favourable 
conditions in a tissue culture incubator. 
 
Neither regular feeding of nutrients, nor the use of a nutrient release gel, led to a 
significant improvement in viability compared to pre-fed cells, though the 
concentrated media was effective in retaining viability within the cell culture at 
room temperature. 
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This thesis aimed to address, at least in part, two separate, fundamental issues with 
regards to translating cell therapy discoveries made within the laboratory to 
therapeutic products that can be routinely used to treat disease. The first 
fundamental issue was to establish whether delivery through narrow, parenteral 
devices, had a detrimental effect on cell viability, apoptosis and function 
(specifically cell attachment, spreading and proliferation) (covered in Chapters 3 
and 4). The second fundamental issue was to determine a means of transporting 
viable cells at room temperature to a clinic without the need for processing at the 
end destination (Chapters 5 and 6).  
 
7.1 – The effect of delivery via narrow-bore needles on cell viability, apoptosis 
and morphology 
7.1.1 – General Discussion and Conclusions 
Recent guidance issued by the regulatory body CBER (Center for Biologics 
Evaluation & Research) suggests that cell therapy products should have a viability 
of 80 % or more and show a repeatably high level of potency72. However, this 
guidance does not suggest at what stage, from culturing the cells within favourable 

 	 conditions to delivering the cells to the patient, this level of viability is 
expected. The research shown in Chapters 3 and 4 assessed whether the delivery 
process, specifically through parenteral devices, affected viability and function of 
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primary murine mesenchymal stem cells (mMSCs), in order to determine whether 
cell viability and potency is affected by the manipulations related to cell delivery.  
 
A significant decrease in viability was seen when mMSCs were processed from 
culture into a concentrated cell suspension, drawn up into a syringe with a 26s 
needle attached (appendix 6) and immediately ejected. This decrease in viability 
was not seen when the cells were processed into a cell suspension but not passed 
through a needle, suggesting that the physical shear stresses experienced as the 
cells move through the narrow bore had a detrimental effect to their survival. The 
noticeable increase in cell debris when comparing cells passed through a needle to 
control suggest that the decrease in viability is due to necrosis, although the 
significant increase in caspase 3-dependent apoptotic activation is also seen.  
 
Leaving the cells within the syringe chamber at room temperature for prolonged 
time periods caused to a further decrease in viability and an increase in apoptosis. 
However, cells that were viable post-ejection were largely found to be functional 
with regard to their ability to spread onto tissue culture plastic (TCP) and their 
ability to proliferate. 
 
When assessing whether changes in processing parameters reduced the decrease in 
cell viability, it was found that reducing the ejection rate or using the antioxidant 

-acetyl cysteine did not significantly improve viability. However, using a wider 
bore needle (22g, 394µm) did improve viability. 
 
Key recommendations for researchers to consider in order to reduce cellular 
damage during administration are to (i) use as wide a needle gauge as possible; (ii) 
restrict the time the cells are within a detached, concentrated cell suspension and 
(iii) if a delay in a surgical procedure does occur, store the cells separate from the 
syringe at room temperature. 
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7.1.2 – Future Development 
The results suggested that the cells that were viable after the delivery process were 
able to perform simple functions, such as attaching to TCP and proliferation. 
However, some other functions that would essential if delivered to a patient, were 
overlooked. An example of this is cell differentiation; it is plausible that this form 
of delivery may impair the cells ability to differentiate into the required cell type, 
or even cause premature differentiation into a cell type different to the required 
cell type. Further studies are required to determine whether these effects occur. 
 
In the study, murine mesenchymal stem cells (mMSCs) specifically were used, 
mainly because of the interest in MSCs as a cell source for cell therapies, as 
discussed in chapter 1. However, it could be argued that MSCs of a murine origin 
may not be representative of human-derived MSCs. There are reports showing 
significant differences in the cellular characteristics between different species131, 
though studies similar to those reported in chapters 3 where the cells were kept 
within eppendorfs, performed using human marrow stromal cells, were found to be 
comparable to the results shown in figure 3.381. Repeated studies using hMSCs are 
required to fully determine whether this is the case. It is hypothesised that, with 
regard to syringe-based manipulations, because the main insult on the cells seemed 
to be caused by the physical shear stresses that the cells experienced as they are 
passed through the needle, the physical parameters of cell size and morphology 
would be related to how they reacted to said stresses. These physical parameters 
differ only slightly when comparing MSCs sourced from humans and mice. In 
addition, it would be expected that cells differing in type or genetic predisposition 
(with regard to autologous cell therapy), with a similar size and morphology, 
would react in similar manner. An acceptable approach that could be used to test 
this hypothesis would be to repeat the study with clinically relevant primary cells 
that clearly differ in size, such as human embryonic stem cells (hESCs) (with 
hESCs being half the diameter of mesechymal stem cells132). 
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Studies have shown that smaller cellular size fractions show more favourable 
proliferation, cell cycle and cell differentiation characteristics compared to their 
larger counterparts133. A reason for this, suggested in some studies, relate to 
isolating a purer stem cell fraction (which are usually charactistically smaller) by 
isolating the smaller cells. However, this difference in size and function may also 
be related to the smaller cells being able to endure the shear stresses related to 
passaging and processing for the studies (described in68) to a greater extent than 
the larger cells. An interesting study would be to assess the passage of cell 
populations differing in size through narrow-bore needles, and assess their 
viability, apoptosis and morphology. 
 
With regard to MP studies, it may be the case that cell viability had decreased with 
the cells seeded to the MPs because of the increased solid mass within the syringe 
chamber, increasing shear stress. This shear stress may be reduced by improving 
the number of cells that were seeded per MP, and therefore reducing the number of 
MPs required. This may show an improvement in viability with the seeded cells 
compared to single cell suspension, as was expected. 
 
Finally, as mentioned in section 4.4, these studies have only assessed the short-
term, direct effects of nAC on the cell cultures, as nAC was only exposed to the 
cells for limited periods of time. By culturing the cells within media containing 
nAC a day before the syringe-based studies were carried out, one may determine 
whether the indirect effects of nAC (namely the activation of glutathione) allows 
the cells to be more tolerant towards the stresses related to the delivery-based 
manipulations. 
 
7.2 – Development of the cell transportation system 
7.2.1 – General Discussion and Conclusions 
The current means of transporting allogeneic cell therapy products are in a 
cyropreserved form, but this form of transportation has a number of drawbacks 
with regard to transport costs, the toxic effects of the cryopreservents and the 
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required processing of the cell suspension at the clinic, compromising sterility. 
Developing a means of transporting viable cells at room temperature would not 
only reduce transportation costs, but the cells could then be carried within a vessel 
that allows the delivery of the cells directly to the patient without any prior 
processing. 
 
In order for such a transportation strategy to be feasible, evidence that clinically 
relevant cells would remain viable under room conditions, was required. The 
results shown in Chapter 5 suggest that, when placed under room conditions, and 
when nutrient supply and toxin dilution is ample through the provision of large 
volumes of culture media, primary human mesenchymal stem cells (hMSCs) enter 
a proliferative arrest phase that is reversible when returned to favourable 
temperatures. Research after this point focused on developing means of reducing 
the volume of culture media in order to make the end transportation vessel more 
compact, reducing production and shipping costs. 
 
It was identified that ammonia was a key toxic metabolite within the culture. 
Zeolite and activated carbon were found to effectively adsorb ammonia from 
solution, but further development was carried out using zeolite alone, as our 
findings, together with the literature125, suggested that zeolite would be able to 
adsorb ammonia more specifically and not adsorb nutrients from the solution to 
the same extent as activated carbon. Zeolite was found to significantly improve 
viability through the partial removal of ammonia. This is one of the first reports of 
using the adsorptive properties of such a material for an application in regenerative 
medicine.  
 
It was realised that the nutrient needs of the cells were complex and that the best 
form of nutrient supply would be a modified form of the xeno-free StemPro® 
media that the cells were cultured in. The freeze-drying method used to 
concentrate the cell culture media appeared to be an effective means of making the 
end transportation device more compact without significantly comprising cell 
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viability. However, it was difficult to dissolve all of the nutrients into the solution 
at a 5 × concentration, so it is unlikely that this method could be used to make a 
media of a higher concentration. 
 
A nutrient release system, using alginate, was developed to assess whether, 
through the prevention of the nutrients reaching toxic concentrations within the 
solution and through the prevention of nutrients being adsorbed by the zeolite 
before being consumed by the cells, the viability of the cells could be further 
improved. However, the nutrient release system did not provide any additional 
benefit compared to providing all the required nutrients at day 0. 
 
In conclusion, the results showed herein suggest that hMSCs remained viable in a 
reversible proliferative arrest phase for up to 4 days under room conditions, 
suggesting that it is feasible to develop a vessel that is able to transport cells under 
such conditions. Zeolite is a toxin adsorbent that showed an ability to adsorb 
ammonia from solution, and its introduction improved the viability of cells 
cultured under room conditions. The use of a controlled nutrient release system 
provided no improvement in cell viability compared to the provision of all 
nutrients at day 0, though a means of concentrating the cell culture media did 
allow a smaller volume of media to be used without compromising cell viability.   
 
7.2.2 – Future Development 
The reversible arrest phase observed is not only a beneficial finding with regard to 
the development of the transportation device, but it is also an interesting 
observation with regards to the cellular mechanisms involved, as there are very 
few reports of reversible arrest in stem cells. Moreover, this is a useful finding for 
transporting cell lines for research purposes; if a cell line needs transporting over a 
short period of time, rather than incurring the costs linked with cyropreserved 
transportation, transportation can instead occur within a sealed container under 
room conditions with little loss in viability. However, as this arrest phase has only  
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Figure 7.1. Schematic of final cell transportation device, showing a side 
(A), top (B), and a focused frontal view of the syringe chamber (C). The 
syringe chamber (I), containing cells seeded onto microparticles (II), would 
consist of a gas-permeable membrane (III), a toxin permeable membrane (IV) 
and a nutrient permeable membrane (V). The cell transportation device would 
be designed as a ready-to-use syringe, with needle (VI), syringe chamber (VII) 
and plunger (VIII) to allow ease of use in the clinic. The system would mainly 
consist of a toxin adsorbent (IX) and a nutrient supply (X). 
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 been observed in hMSCs, these studies would need to be applied to a wide variety 
of cells in order to determine whether a similar cell state is seen. 
 
Research is also required in order to assess how cells react to a variety of 
temperatures other than what has been referred to as “room” temperatures. All 
previous experiments had been carried out within cell culture facilities that were 
maintained at a temperature of about 20 °C, but it would be envisioned that, during 
transportation throughout the winter months across continental countries, the 
temperatures the cells would experience would be much lower than 20 °C. For this 
reason, it would be important to determine whether cell viability was significantly 
affected by temperatures closer to freezing. 
 
With regards to the development of the transportation device, figure 7.1 depicts 
how the vessel may appear. Key components of the transportation device include 
the following:- 
The device would be in the form of a syringe, with a needle (or a luer lock 
adaptor to allow the attachment of a needle) and plunger, so no manipulations 
of the cell suspension are required other than the delivery into the patient. This 
would ensure that the cell suspension remains sterile. 
- The device would consist largely of 3 sections, the syringe chamber 
(containing cells), the nutrient release and the toxin adsorbent. Through the 
results shown in figure 6.7, the nutrient supply and toxin adsorbent should be 
kept separate to create an osmotic gradient of nutrients across the cells and to 
ensure that no nutrients are adsorbed from the nutrient supply by the adsrobent 
before reaching the cells. 
- The syringe chamber would be a relatively small part of the syringe device, to 
ensure that the volume of liquid delivered to the patient is kept to a minimum. 
If the cells being transported are attachment-dependent, the cells would be 
pre-seeded onto a microparticle (MP) scaffold, such as the poly(glycolic--
lactic acid) (PLGA) MPs described in chapter 3. Because polymers such as 
- 
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PLGA are approved by regulatory bodies to be inserted into the body, the MPs 
could be delivered to the patient together with the cells. 
- The toxin adsorbent would consist of a form of zeolite material for ammonia 
removal. This adsorbent would need to be in solution for effective adsorption 
to occur. Analysis of zeolite modification is required to determine whether the 
adsorptive capacity can be improved, which would allow the volume of 
zeolite required to be reduced. Modifications include those suggested by 
Sprynskyy ; they showed that zeolite that had been cation-modified had 
improved ammonia-adsorptive properties128. 
- The nutrient supply would not be in the form of a gel, but would be 
concentrated media liquid. The nutrient compartment may not be the same 
size as the toxin adsorbent section, in contrary to what is shown in figure 7.1, 
as the volume of zeolite used in chapter 6 was greater than the volume of 
concentrated media. 
- Separating the nutrient supply, syringe chamber and the toxin absorbent 
would be a membrane that is permeable to nutrients and toxins, but not to 
cells. The design of the membrane would be simplified if the cells were 
seeded onto MPs, as the pore size of the membrane could be increased to one 
that only retains the MPs. The membrane would need to be stiff, so that the 
plunger can flow smoothly through the syringe chamber without any flex, to 
ensure all of the cell suspension is delivered and not left within the syringe. 
The volume of liquid used to fill the syringe would also need to be very 
accurate to ensure that no air bubbles were within the syringe, so that, when 
the plunger is pushed, only liquid cell suspension would be ejected. 
- An opening at the top of the transportation device would allow the passage of 
gases to and from the syringe chamber containing the cells via a gas 
permeable membrane. This part of the syringe would be complicated to 
design, as the membrane would still need to be stiff for the reasons discussed 
above, but allow gases through without liquid. Polytetrafluoroethylene (Gore-
tex®) material, (currently used in waterproof, breathable clothing), has been 
shown to be biocompatible and used as breathable surgical barrier fabric134. 
Chapter 7   General discussion, conclusions and future developments 
   
  120 
Polydimethylsiloxane (PDMS) is another polymer known for its gas 
permeable properties, and has been shown to be effective as a cellular 
substrate within a bioreactor135. These polymers may have the properties 
required for this device. 
- The transportation device would be disposable, being made of relatively cheap 
materials similar to those utilised in syringes used currently in the clinic. A 
disposable device would ensure that the cell suspension delivered was sterile. 
The toxin adsorbent, although difficult to source, is inexpensive, so the most 
expensive part of the device would be the cell culture media. 
 
The demand for such a device relies heavily on the successful identification of a 
specific allogeneic cell source being effective in treating a disease state. 
Furthermore, the global demand to treat the identified disease state would need to 
be great, both in terms of the number of patients with the disease and in terms of 
the current cost for treating the disease. This is because the cost of developing and 
producing such a cell therapy product would arguably be far greater than the cost 
of developing the equivalent pharmaceutical product. However, the number of 
reports suggesting that effectiveness of ESCs and induced pluripotent stem cells in 
a wide variety of disease states is increasing. Moreover, some of these allogeneic 
therapies are now moving from the developmental and animal trial stages to 
clinical trials; the FDA has recently approved its first clinical trial using ESC-
derived products in the form of a glial oligodendrocyte injection for complete 
spinal cord injury repair, developed by the Geron Corporation136. These 
oligodendrocytes are not seeded onto any form of scaffold or conduit; instead this 
product is a form of cell therapy that is cyropreserved for transportation 
purposes137. The development of such a product is very encouraging for the work 
described in chapters 5 and 6, as the first trial approval gives confidence to the 
other companies developing cell therapy products138, all of which may benefit 
from the cell transportation device described here, thus establishing a potential 
stable market for this product in the future.  
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1 – Media and Supplements 
1.1 – mMSC Complete Medium 
Dulbecco’s modified Eagle’s Medium (DMEM) (GibcoBRL, UK) 500 ml 
L-Glutamine (GibcoBRL, UK) (200 mM) 5 ml 
Anibiotic/antimycotic Solution (containing penicillin (10000 units), 5 ml 
streptomycin (10000 µg) and amphotericin B (125 µg) in 0.85 % w/v saline  
(GibcoBRL, UK)) 
Foetal calf serum (FCS) (heat-inactivated (56ºC for 1h)) (Sigma- 50 ml 
Aldrich, Poole, UK) 
Non-essential amino acids (Sigma-Aldrich, Poole, UK) 5 ml 
All supplements were passed through a 0.2 µm filter into the medium. Stored at 4 
°C 
 
1.2 – Serum-supplemented hMSC Medium 
Mesenchymal stem cell medium (MSCM) (TCS Cell Works, UK) 500 ml 
FCS (TCS Cell Works, UK) 25 ml 
Mesenchymal stem cell growth medium (TCS Cell Works, UK) 5 ml 
Penicillin/streptomycin solution (TCS Cell Works, UK) 5 ml 
L-Glutamine (GibcoBRL, UK) (200 mM) 5 ml 
Non-essential amino acids (Sigma-Aldrich, Poole, UK) 5 ml 
All supplements were passed through a 0.2 µm filter into the MSCM. Stored at 4 
°C 
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1.3 – Serum-free hMSC Medium 
StemPro® MSC serum free basal medium (Invitrogen, UK) 500 ml 
StemPro® MSC serum free medium supplement (Invitrogen, UK) 75 ml 
Anibiotic/antimycotic Solution (containing penicillin (10000 units), 5 ml 
streptomycin (10000 µg) and amphotericin B (125 µg) in 0.85 % w/v saline  
(GibcoBRL, UK)) 
Glutamax® Supplement (Sigma Aldrich, Poole UK) 5 ml 
Non-essential amino acids (Sigma-Aldrich, Poole, UK) 5 ml 
All supplements were passed through a 0.2 µm filter into the basal media. Stored 
at 4 °C 
 
1.4 – Concentrated StemPro® Medium 
StemPro® MSC serum free basal medium (Invitrogen, UK) 500 ml 
Freeze-dry solution, so that all liquid is removed 
Tissue Culture Water 28 ml 
StemPro® MSC serum free medium supplement (Invitrogen, UK) 75 ml 
Anibiotic/antimycotic Solution (containing penicillin (10000 units), 5 ml 
streptomycin (10000 µg) and amphotericin B (125 µg) in 0.85 % w/v saline  
(GibcoBRL, UK)) 
Glutamax® Supplement (Sigma Aldrich, Poole UK) 5 ml 
Non-essential amino acids (Sigma-Aldrich, Poole, UK) 5 ml 
Placed on shaker at 37 ºC for 2 hours. pH-adjusted using 100 mM hydrochloric 
acid. Passed through a 0.2 µm filter. Stored at 4 °C 
 
1.5 – Phosphate buffered saline (PBS) (0.01 M pH 7.4) 
PBS (Dulbecco’s A) tablets (Oxoid, UK) 1 tablet 
Made up to 100 ml in distilled water and heat sterilized. 
 
1.6 – Ethylenediaminetetraacetic acid (EDTA) stock solution (2 %) 
EDTA (Sigma, UK) 0.5 g 
Made up to 25 ml with PBS 
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1.7 – Trypsin/EDTA solution 
Trypsin (Sigma, UK) 2.5 % 10 ml 
EDTA (2 %) 1 ml 
Made up to 100 ml with PBS, filter sterilized and stored at - 20 °C 
 
1.8 – Freezing Medium (Sigma-Aldrich, Poole, UK) 
DMSO 2 ml 
Foetal calf serum (FCS) (heat-inactivated (56ºC for 1h)) 18 ml 
Passed through a 0.2 µm filter and used immediately 
 
2 - Stains and assay reagents 
2.1 – CaspACE® Assay (Promega, UK) 
Caspase Assay Buffer 160 µl 
DMSO (Sigma-Aldrich, Poole, UK) 10 µl 
DTT (Sigma-Aldrich, Poole, UK) 50 µl 
Cell Extract 10µl 
Distilled H2O to 490 µl 
Gently vortexed, incubated at 37 °C, 5 % CO2, for 30 minutes 
Caspase-3 substrate (10 mM) 2.5 µl 
DMSO 7.5µl 
 
2.2 – Live/Dead® Viability/Cytotoxicity Kit L-3224 (Invitrogen, UK) 
Ethidium homodimer-1 (EthD-1) (2 mM in DMSO/H2O 1:4 
v/v) 20 µl 
PBS 10 ml 
Vortex solution 
Calcein AM (4 mM in DMSO) 5 µl 
Used immediately 
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2.3 – Mitotracker® Deep Red M-22426 (Invitrogen, UK) 
Mitotracker® Deep Red 50 µg 
DMSO 92 µl 
Once reconstituted, the solution was added immediately to 200 ml of serum-
supplemented hMSC medium, resulting in a 500 nM solution of Mitotracker® 
Deep Red 
 
2.4 – Glucose Oxidase assay (Sigma-Aldrich, Poole, UK) 
Glucose oxidase/peroxidase reagent 4.9 ml 
o-dianisidine reagent 100 µl 
 
2.5 – BioVision® Ammonia Assay (Cambridge Bioscience, UK) 
Ammonia Assay Buffer 44 µl 
OxiRed Probe 2 µl 
Enzyme Mix 2 µl 
Converting Enzyme 2 µl 
 
3 – Other Solutions 
3.1 – Paraformaldehyde solution (3.7 % w/v) 
Paraformaldehyde (Sigma-Aldrich, Poole, UK) 3.7 g 
Sodium Hydroxide (1 M) 8 ml 
0.2 M phosphate buffer 50 ml 
Distilled H2O 100 ml 
Stored at -20 °C for upto 1 year 
 
3.2 – Triton-X 100 solution (0.1 % v/v) 
Triton-X 100 (Sigma Aldrich, Poole, UK) 20 µl 
PBS to 20 ml 
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3.3 – Poly vinyl acetate (PVA) solution (0.3 %) 
PVA (Sigma-Aldrich, Poole, UK) 3 g 
Distilled water 1 L 
Stirred at room temperature overnight and filtered before use 
 
3.4 – Alginate Polymerisation Buffer 
20 % Barium Chloride solution (Sigma-Aldrich, Poole, UK) (1 or 5 or 10 ml 
2 %) 
Sodium Chloride (Sigma-Aldrich, Poole, UK) (145 mM) 877 mg 
100 mM HEPES solution (Sigma-Aldrich, Poole, UK) (10 mM) 10 ml 
Distilled H2O  to 100 ml 
 
4- General Cell Maintenance 
4.1 – Cryopreservation 
Prior to storage, cell cultures were maintained in an actively growing state to 
ensure optimum health and good recovery. A minimum concentration of 5 x 106
 
cells/ml were detached from the culture vessel before being re-suspended in a 
freezing medium (appendix 1.8). This cell homogenate was then aliquotted into 
cryogenic storage vials and placed into an isopropanol-containing cryo-container 
(Mr Frosty, Sigma, Poole, UK), before being ‘stepped-frozen’- by placement into 
a -80 °C freezer for 24 hours, after which the vials were transferred to liquid 
nitrogen for further long-term storage. 
 
4.2 – Cell Revival from Storage 
Cells were removed from storage and placed directly into a tissue culture incubator 
until thawed. Immediately after thawing, the cell suspension was slowly 
introduced into a T 75 cm2 flask containing complete, pre-warmed media. The cell 
were allowed to attach within a tissue culture incubator for 24 hours before the 
medium was changed to remove the DMSO from the culture. 
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4.3 – Trypan Blue Exclusion Assay 
Cell counts and viability estimations were performed using the trypan blue 
exclusion technique by means of a 0.22 µm sterile filtered 0.5 % (w/v) trypan blue 
solution and a haemocytometer. An equal volume of the cell suspension and of the 
stain were mixed and transferred onto a haemocytometer. The cells within at least 
5 separate squares (and at least 100 cells) were counted under a light-inverted 
microscope. The average cell number per square was determined, and a 
multiplication of 104 gave the cellular concentration (cells/ml).  
 
Non-viable cells stained blue due to the loss of their membrane integrity and, 
hence, allowed the passage of dye into the cell. Viable cells remained colourless. 
 
5 – Standard Curve Derivation 
5.1 - CellTiter AQ One Solution Cell Proliferation® assay 
Cell suspensions were created into 100 µl aliquots, using mMSC media, 
containing the following cellular concentrations in 104 cells/ml: 100, 80, 60, 40, 
30, 20, 10, 5, 2.5 0. These solutions were added to 20 µl CellTiter AQ Reagent 
(Promega, Southampton, UK), incubated in a tissue culture incubator for 1 hour, 
and analysed colorimetrically (492 nm) using a Bio-Tek KC4 plate reader (Fisher 
Scientific, Loughborough, UK). 
 
5.2 – CaspACE® assay 
-nitroaniline (100 mM solution) (Promega, Southampton, UK)  1 µl 
Made up to 1 ml using PBS, resulting in a 100 µM solution. From this solution, 
100, 50, 10, 5, 2, 1 and 0 µl were diluted with PBS to create 100 µl solutions of the 
following concentrations in µM: 100, 50, 10, 5, 2, 1 and 0. The solutions were 
transferred to a 96-well plate and analysed colorimetrically (405 nm) using a Bio-
Tek KC4 plate reader (Fisher Scientific, Loughborough, UK). 
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5.3 – Bradford assay 
Bovine γ Globulin (Sigma-Aldrich, Poole, UK) 2 mg 
Made up to 1 ml with serum-free mMSC media. From this solution, serial 
dilutions were performed to provide 5 µl of solution at the following 
concentrations in µg/ml: 2000, 1000, 500, 250, 125 and 0. These solutions were 
added to 250 µl Bradford reagent (Sigma-Aldrich, Poole, UK), agitated for 5 
minutes, and analysed colorimetrically (595 nm) using a Bio-Tek KC4 plate reader 
(Fisher Scientific, Loughborough, UK). 
 
5.4 – Alamar Blue assay 
Alamar Blue Reagent (Invitrogen, Paisley, UK) 15 ml 
StemPro® media (Invitrogen, Paisley, UK)  150 ml 
Cell suspensions were created into 10 ml aliquots, using the Alamar Blue solution, 
containing the following cellular concentrations in 103 cells/ml: 10, 5, 2.5, 1.25, 0. 
These solutions incubated in a tissue culture incubator for 2 hours, and analysed 
fluorometrically ( ex 560 nm/ emm 590 nm) nm using a Dynex MFX plate reader 
(Chantilly, VA, USA). 
 
5.5 – Coomassie Plus assay 
Bovine γ Globulin (Sigma-Aldrich, Poole, UK) 2 mg 
Made up to 1 ml with PBS. From this solution, serial dilutions were performed to 
provide 30 µl of solution at the following concentrations in µg/ml: 2000, 1000, 
500, 250, 125 and 0. These solutions were added to 1.5 ml Coomassie Plus reagent 
(Thermo Fisher Scientific, Loughborough, UK), agitated for 1 minute, and 
analysed colorimetrically (595 nm) using a Bio-Tek KC4 plate reader (Fisher 
Scientific, Loughborough, UK). 
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5.6 – Glucose oxidase assay 
Glucose Standard (100 mg/ml) (Sigma-Aldrich, Poole, UK) 500 µl 
From this solution, 100, 80, 60, 40, 20 and 0 µl were diluted with PBS to create 
100 µl solutions of the following concentrations in mg/ml: 100, 80, 60, 40, 20 and 
0. The solutions were added to 200 µl of glucose assay reagent (appendix 2.4), 
incubated within a tissue culture incubator for 30 minutes, and analysed 
colorimetrically (540 nm) using a Bio-Tek KC4 plate reader (Fisher Scientific, 
Loughborough, UK). 
 
5.7 - Biovision® Ammonia Assay 
Ammonium Chloride Standard Solution (100 mM) (Cambridge  10 µl 
Bioscience, UK) 
This stock solution was diluted with 990 µl tissue culture water to provide a 1 mM 
concentration. From this solution, 10, 8, 6, 4, 2 and 0 µl were diluted with 
ammonia assay buffer (Cambridge Bioscience, UK) to create 50 µl solutions of the 
following concentrations in µM: 200, 160, 120, 80, 40 and 0. The solutions were 
added to 50 µl of ammonia assay reaction mix (Appendix 2.5), incubated within a 
tissue culture incubator for 60 minutes, and analysed colorimetrically (570 nm) 
using a Bio-Tek KC4 plate reader (Fisher Scientific, Loughborough, UK). 
 
6 – Corresponding needle diameters and needle areas for the needle gauges 
used 
 
Needle Gauge Internal Needle 
Diameter (µm) 
Circular Needle 
Area (µm
2
) 
26s 114 10207 
25 241 45617 
22 394 121922 
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7 – Mathematical derivation of the shear stresses experienced by water 
through narrow bores (Table 4.5) 
 
 
 
 
 
 
 
The figure above shows how a liquid would flow in a laminar manner through a 
bore under non-slip conditions, i.e. the velocity at the boundary interface = 0. 
Using the figure above, shear stress (τ) can be defined as µ × (=), where µ is 
the co-efficient of viscosity (for water, this value is 1.003 × 10-3 Pa.s) and = is 
the gradient of the velocity compared to distance from the boundary, as shown in 
the figure118. 
 
The velocity at which the liquid travels through the bore is dependent on the 
diameter of the bore. In order to convert the velocity from µl/min to mm/s, the 
equation πr2l was used to determine the volume of the bore (where r is the bore 
radius and l is the length). Substituting the rate in µl/min (which is equivalent to 
mm3/min) for the volume and the length for the rate in mm/s gives this equation; 
Rate (mm/s) = rate (mm3/min) / (πr2 × 60) (divide by 60 to convert minutes to 
seconds). 
 
The derived velocity in mm/s is used in the 1st equation;  
τ (Pa) = (µ (Pa.s) × rate (mm/s) × 2) / r (the equation needs to multiplied by 2, as, 
from the side on view of the bore in the figure, the liquid is affected by the shear 
stress both at the bottom and the top of the bore, therefore the shear stress is 
doubled. 
 
 
 = 
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As a working example, if one were to determine the shear stress experienced on 
water as it moved through a 26s needle at a rate of 1 µl/min, one would first need 
to convert the velocity from µl/min to mm/s: 
Rate (mm/s) = rate (mm3/min) / (πr2 × 60 s/min) 
= 1 mm3/min / (π × (0.057mm)2 × 60 s/min) = 1.62 mm/s 
 
This velocity is then applied to the shear stress equation: 
τ (Pa) = (µ (Pa.s) × rate (mm/s) × 2) / r 
 (1.003 × 10-3 Pa.s × 1.62 mm/s × 2) / 0.057 mm = 57.0 mPa 
 
Some assumptions were made in order to derive these shear stress values. The 
assumptions made were:- 
· The temperature was at 20 ºC (as the viscosity of water changes with 
temperature)118 
· The flow through the needle was thought to be laminar. This might not have 
been the cases through the narrower needles at the faster ejection rates, where 
turbulent flow may have occurred118 
· The boundary layer (the layer near the boundary where the liquid is not 
flowing at its maximal velocity) was assumed to be equal to the radius, as 
shown in the figure (i.e. the liquid was only flowing at maximal velocity in the 
centre of the bore). The thickness of the boundary layer is dependent on the 
level of friction caused by the inner surface of the needle, and this could not 
be determined118 
· The average gradient of velocity with respect to distance from boundary 
(=) was assumed to be equal to the maximal velocity with respect to bore 
radius. As shown in the figure, this average gradient would probably be 
greater than what is calculated, but this is difficult to determine 
mathematically and also depends on the level of friction that occurs118 
